



A phospholipase A 1 antibacterial Type VI secretion effector interacts directly with the C-terminal domain of the VgrG spike protein for delivery

Nicolas Flaugnatti, Thi Thu Hang Le, Stéphane Canaan, Marie-Stéphanie Aschtgen, Vân Nguyễn, Stephanie Blangy, Christine Kellenberger, Alain Roussel, Christian Cambillau, E. Cascales, et al.

► To cite this version:

Nicolas Flaugnatti, Thi Thu Hang Le, Stéphane Canaan, Marie-Stéphanie Aschtgen, Vân Nguyễn, et al.. A phospholipase A 1 antibacterial Type VI secretion effector interacts directly with the C-terminal domain of the VgrG spike protein for delivery. *Molecular Microbiology*, 2016, 99 (6), pp.1099 - 1118. 10.1111/mmi.13292 . hal-01778571

HAL Id: hal-01778571

<https://amu.hal.science/hal-01778571>

Submitted on 25 Apr 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**A phospholipase A₁ anti-bacterial T6SS effector interacts directly with the C-terminal domain
of the VgrG spike protein for delivery**

Nicolas Flaugnatti¹, Thi Thu Hang Le^{2,3}, Stéphane Canaan⁴, Marie-Stéphanie Aschtgen^{1¶}, Van
Son Nguyen^{2,3}, Stéphanie Blangy^{2,3}, Christine Kellenberger^{2,3}, Alain Roussel^{2,3}, Christian
Cambillau^{2,3}, Eric Cascales¹ and Laure Journet^{1*}

¹ Laboratoire d'Ingénierie des Systèmes Macromoléculaires, CNRS – Aix-Marseille Université, UMR 7255, Institut de Microbiologie de la Méditerranée, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 20, France

² Architecture et Fonction des Macromolécules Biologiques, CNRS – UMR 7257, Campus de Luminy, Case 932, 13288 Marseille Cedex 09, France

³ Architecture et Fonction des Macromolécules Biologiques, Aix-Marseille Université, Campus de Luminy, Case 932, 13288 Marseille Cedex 09, France

⁴ CNRS – Aix-Marseille Université – Laboratoire d'Enzymologie Interfaciale et de Physiologie de la Lipolyse, UMR 7282, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 20, France.

¶ Present address: Laboratoire des Sciences de l'Environnement Marin (LEMAR), Institut Universitaire Européen de la Mer (IUEM), Université de Bretagne Occidentale, CNRS, IRD, Ifremer – UMR 6539, Technopôle Brest Iroise, 29280 Plouzané, France.

* To whom correspondence should be addressed: Laure Journet. Laboratoire d'Ingénierie des Systèmes Macromoléculaires (UMR7255), CNRS, Aix-Marseille Université, 31 Chemin Joseph Aiguier, 13402 Marseille cedex 20, France. Tel.: 33491164156; Fax: 33491712124; E-mail: ljournet@imm.cnrs.fr

SUMMARY

The Type VI secretion system (T6SS) is a multi-protein machine that delivers protein effectors in both prokaryotic and eukaryotic cells, allowing interbacterial competition and virulence. The mechanism of action of the T6SS requires the contraction of a sheath-like structure that propels a needle toward target cells, allowing the delivery of protein effectors. Here, we provide evidence that the entero-aggregative *Escherichia coli* Sci-1 T6SS is required to eliminate competitor bacteria. We further identify Tle1, a toxin effector encoded by this cluster and showed that Tle1 possesses phospholipase A₁ and A₂ activities required for the inter-bacterial competition. Self-protection of the attacker cell is secured by an outer membrane lipoprotein, Tli1, which binds Tle1 in a 1:1 stoichiometric ratio with nanomolar affinity, and inhibits its phospholipase activity. Tle1 is delivered into the periplasm of the prey cells using the VgrG1 needle spike protein as carrier. Further analyses demonstrate that the C-terminal extension domain of VgrG1, including a transthyretin-like domain, is responsible for the interaction with Tle1 and its subsequent delivery into target cells. Based on these results, we propose an additional mechanism of transport of T6SS effectors in which cognate effectors are selected by specific motifs located at the C-terminus of VgrG proteins.

INTRODUCTION

The T6SS is built by the assembly of at least 13 proteins encoded by usually clustered genes. A trans-membrane complex anchors to the cell envelope a phage-like tail complex that extends from the membrane in the cytoplasm (Coulthurst, 2013; Zoued *et al.*, 2014; Ho *et al.*, 2014; Basler, 2015). The membrane complex serves as docking station for assembly of the tail complex (Durand *et al.*, 2015), a dynamic tubular structure functionally and structurally homologous to the contractile tail of bacteriophages (Bönemann *et al.*, 2009; Leiman *et al.*, 2009; Bönemann *et al.*, 2010; Basler *et al.*, 2012). It is constituted of an inner tube made of stacked hexameric rings of the Hcp protein, whose three-dimensional structure is very similar to that of the bacteriophage tail tube gpV (Mougous *et al.*, 2006; Pell *et al.*, 2009; Ballister *et al.*, 2008; Brunet *et al.*, 2014; Douzi *et al.*, 2014). This Hcp edifice resembles a channel-like tubular structure with a 40-Å internal diameter and is surrounded by a contractile sheath made of the TssB and TssC proteins (Kudryashev *et al.*, 2015). The inner tube/sheath structure is built on an assembly platform – the baseplate – that contacts the membrane complex (Brunet *et al.*, 2015). The TssBC sheath is highly dynamic. Cycles of sheath assembly, contraction and disassembly were visualized by time-lapse fluorescence microscopy using fluorescent TssB–sfGFP fusion constructs (Basler *et al.*, 2012; Brunet *et al.*, 2013; Kapitein *et al.*, 2013). The inner tube is capped by the spike composed of a VgrG (valine glycine repeat protein) trimer. This complex is structurally homologous to the bacteriophage T4 gp27-gp5 cell-puncturing device (Leiman *et al.*, 2009). The VgrG trimer global fold consists of a gp27-like trimer, followed by the N-terminal OB fold domain of gp5 and a three-stranded β -helix that forms the needle of the spike complex. In some T6SSs, an additional component called PAAR (Pro-Ala-Ala-Arg motif-containing protein) assembles a conical structure at the tip of the VgrG protein (Shneider *et al.*, 2013). This

component was proposed to sharpen the VgrG spike, assist folding and to stabilize the β -helix domain of VgrG or to be used as an adaptor component mediating interaction between VgrG and effector proteins (Shneider *et al.*, 2013). The contractile structure assembles in an elongated metastable state. Upon contact with a target cell, the sheath contraction is thought to propel the Hcp inner tube towards the target cell, piercing the membrane using the VgrG/PAAR spike complex, hence leading to effector delivery (Cascales, 2008; Silverman *et al.*, 2012; Coulthurst, 2013; Ho *et al.*, 2014; Zoued *et al.*, 2014). In agreement with this mechanism of action, time-lapse fluorescence recordings demonstrated that contraction of the sheath is correlated with lysis of the prey cell (Brunet *et al.*, 2013).

The T6SS is a versatile machinery as it has been shown to have roles in both pathogenesis and inter-bacterial competition, and effectors that have eukaryotic or prokaryotic targets have been identified and characterized (Russell *et al.*, 2014; Durand *et al.*, 2014, Alcoforado Diniz *et al.*, 2015). For examples, the *Vibrio cholerae* and *Aeromonas hydrophila* T6SSs disable eukaryotic cells by delivering specific effector modules that interfere with the actin cytoskeleton dynamics (Pukatzki *et al.*, 2006; Pukatzki *et al.*, 2007; Suarez *et al.*, 2010; Durand *et al.*, 2012) while a growing number of T6SSs have been demonstrated to have anti-bacterial activities (Hood *et al.*, 2010; Schwarz *et al.*, 2010; MacIntyre *et al.*, 2010; Murdoch *et al.*, 2011; Gueguen *et al.*, 2013; Brunet *et al.*, 2013; Carruthers *et al.*, 2013). In fact, bacteria do not live alone in their environment: they share the same ecological niche, socialize, but also display antagonistic behaviours and compete with each other. The T6SS is one of the key players during the bacterial warfare by delivering anti-bacterial effectors directly into bacterial competitor cells (Coulthurst, 2013; Ho *et al.*, 2014; Durand *et al.*, 2014, Alcoforado Diniz *et al.*, 2015). Among these effectors, the Tae (type VI secretion amidase effector) and Tge (type VI secretion glycoside hydrolase effector) effectors degrade the peptidoglycan of the target cells, the Tle (type VI lipase effectors) toxins hydrolyse the membrane phospholipids of the

target cells whereas the Tde (type VI DNase effectors) are nucleases (Russell *et al.*, 2014; Benz and Meinhart, 2014; Durand *et al.*, 2014). Recently, the *P. aeruginosa* Tse6 T6SS effector has been demonstrated to have NAD(P)⁺ glycohydrolase activity, hence depleting the NAD(P)⁺ pool of the target cell (Whitney *et al.*, 2015). The cell wall degrading effectors target the peptide stem (Tae) or the glycan strands (Tge) of the peptidoglycan and can be divided in several families with different hydrolysed bond specificities (Russell *et al.*, 2014; Benz and Meinhart, 2014; Durand *et al.*, 2014). Tle toxins consist to a large group of enzymes that could be divided into five divergent families bearing phospholipase A₁, A₂ or D activities (Russell *et al.*, 2013). Interestingly, whereas the Tae and Tge toxins are anti-bacterial only, members of the Tle or Tde toxin families target macromolecules present in both eukaryotic and prokaryotic cells. Indeed, a number of Tle toxins have been shown to cause damages in eukaryotic cells, such as the *P. aeruginosa* PldB (Tle5b^{PA}) protein that promotes invasion of eukaryotic cells by activation of the AKT/PI3pathway (Jiang *et al.*, 2013) or the Tle2^{VC} toxin that is necessary for *V. cholerae* to escape amoeba predation (Dong *et al.*, 2013).

To prevent self-intoxication, Tae, Tge, Tle and Tde anti-bacterial effectors are produced concomitantly with cognate immunity proteins, called Tai, Tgi, Tli and Tdi, respectively (Russell *et al.*, 2014; Benz and Meinhart, 2014; Durand *et al.*, 2014). Usually, the immunity protein resides in the compartment in which the toxin is delivered, binds to the toxin with high (nanomolar) affinity and inhibits it, either by the occlusion of the catalytic site or by preventing access to its target (Russell *et al.*, 2014; Benz and Meinhart, 2014; Durand *et al.*, 2014).

T6SS toxins exist either as independent proteins or additional modules fused to the Hcp, VgrG or PAAR components. These effector modules are hence delivered into the target cell upon sheath contraction. The cargo mechanisms by which independent effectors are delivered into the target cell is less known. The current transport models propose that these effectors bind to the Hcp, VgrG or PAAR proteins directly or via adaptor proteins, and therefore that these structural components of the

machine are used as carriers (Silverman *et al.*, 2013; Shneider *et al.*, 2013; Hachani *et al.*, 2014; Durand *et al.*, 2014). Indeed, the *P. aeruginosa* Tae1 and Tge1 effectors are embedded into the lumen of the Hcp ring and are stored into the Hcp inner tube before sheath contraction (Silverman *et al.*, 2013). It has been suggested that several *P. aeruginosa* effectors bind directly or indirectly to VgrG (Dong *et al.*, 2013; Whitney *et al.*, 2014; Hachani *et al.*, 2014). Hachani *et al.* suggested that VgrG/effector combinations are not interchangeable and that selection of the effector depends on specific motifs on VgrG (Hachani *et al.*, 2014). More recently, conserved T6SS adaptor proteins linking VgrG and cognate effectors were identified (Alcoforado Diniz and Coulthurst, 2015; Unterweger *et al.*, 2015; Liang *et al.*, 2015).

In the recent years we have characterized the regulatory mechanisms and the structural architecture of the entero-aggregative *E. coli* (EAEC) Sci-1 Type VI secretion system (T6SS-1). However, the function of this T6SS has remained elusive and no T6SS-1 substrate has been identified. The EAEC *sci-1* gene cluster encodes the 13 core components, a PAAR protein, the TagL accessory protein, and 6 genes of unknown function. Among these genes, a gene encoding a putative Tle1 effector followed by a gene encoding a putative lipoprotein is found downstream *vgrG1*. In this study, we demonstrate that the Sci-1 T6SS is required for EAEC antibacterial activity in minimal medium and that Tle1^{EAEC} possesses phospholipase A₁ (PLA₁) and A₂ (PLA₂) activities responsible for the antibacterial activity of Sci-1 T6SS. We then show that Tli1^{EAEC} is an outer membrane immunity lipoprotein that binds tightly to Tle1^{EAEC} and inhibits its PLA activity. Finally, we demonstrate that Tle1^{EAEC} is a cargo effector and is delivered into target cells using the VgrG1 spike as carrier through direct interaction with the VgrG1 C-terminal extension.

Results

The EAEC T6SS *sci-1* gene cluster has anti-bacterial activity in minimal medium.

To gain insights into the function of the Sci-1 T6SS, we compared the EAEC 17-2 wild-type (WT) strain with its derivative strain deleted of the entire *sci-1* gene cluster ($\Delta T6SS-1$) for (i) virulence towards eukaryotic cells using the *Caenorhabditis elegans* model of infection and (ii) antagonism against competitor bacteria. The experiments were performed in NGM or *sci-1* inducing minimal media (SIM) to allow maximal expression of the *sci-1* gene cluster (Brunet *et al.*, 2011). In these conditions, the growth rates of the WT strain and its isogenic $\Delta T6SS-1$ mutant were comparable (data not shown).

In *C. elegans*, the WT EAEC 17-2 cells were moderately virulent, with a lethal dose 50% (LD₅₀) of 7 days (compared to 3 days for *Burkholderia cenocepacia* K56-2). Identical values were obtained when $\Delta T6SS-1$ cells were used as feeding source for the worms (Fig. 1A). These data suggest that the T6SS-1 is not involved in the virulence of EAEC 17-2 in the *C. elegans* model of infection. The anti-bacterial activity was therefore tested in SIM. The *E. coli* K-12 strain W3110 (devoid of T6SS genes) engineered to constitutively produce the green fluorescent protein (GFP) and to resist kanamycin was used as prey. Attacker and prey cells were mixed in a 4:1 ratio and the mixtures were spotted on SIM agar plates. After a 4-hour incubation at 37°C, the fluorescence levels and the number of kanamycin-resistant colony-forming units (cfu) were measured to estimate the survival of the prey cells (Fig. 1B). In these conditions, the deletion of the *sci-1* gene cluster increased the recovery of prey cells. We therefore concluded that the T6SS-1 machine provides anti-bacterial activity in minimal medium.

The *EC042_4534* gene product encodes an anti-bacterial effector with phospholipase A₁ and A₂ activities.

To identify potential effector toxins, we screened the *sci-I* gene cluster. The *sci-I* gene cluster encodes the 13 T6SS core-components, *PAAR* and a number of genes of unknown function (Fig 2A). Among those, a group of three genes, *EC042_4534*, *EC042_4535* and *EC042_4536* is found between the *vgrG1* (*EC042_4533*) and *PAAR* (*EC042_4537*) genes. *EC042_4534* (NCBI Gene Identifier (GI): 284924255) is encoded directly downstream *vgrG1*. Computer analysis of the *EC042_4534* gene product using Pfam predicts it carries a DUF2235 domain (uncharacterized α/β hydrolase domain, amino-acid 36 to 333, E-value 9.7 e-24). A phylogenetic reconstruction of *EC042_4534* with members of Type VI lipase effector (Tle) families 1 to 5 (as defined by Russell *et al.*, 2013) showed that *EC042_4534* segregates with Tle1 members (Fig. S4). Multiple alignments of *EC042_4534* with Tle1 members revealed the characteristic GX SXG motif usually found in lipases and some phospholipases (Fig. S5). Fold recognition servers (such as Phyre2, Kelley and Sternberg, 2009) suggest significant homologies between *EC042_4534* and the D1 catalytic domain of the *Pseudomonas aeruginosa* Tle1^{PA} protein (Hu *et al.*, 2014; data not shown). The structure of *EC042_4534* was modelled using the structure of Tle1^{PA} (Protein Data Bank (PDB) identifier 4O5P, Hu *et al.*, 2014) as template (Fig 2B). As expected, the structural model predicts that the catalytic triad is composed of the Ser-197, Asp-245 and His-310 amino acids (Fig. 2B). *EC042_4534* protein is thus a putative member of the Tle1 family of T6SS effectors and was therefore named hereafter Tle1^{EAEC}.

In order to biochemically characterize Tle1^{EAEC}, its coding sequence was cloned into the pETG20A *E. coli* expression vector, fused to a N-terminal hexahistidine-tagged thioredoxin domain followed by a Tobacco Etch Virus (TEV) cleavage site. The wild-type Tle1^{EAEC} protein

(Tle1^{EAEC(WT)}) and a variant bearing a mutation in the putative catalytic triad (Tle1^{EAEC(S197A)}) were purified to homogeneity using ion metal affinity chromatography and gel filtration, and the recombinant Tle1^{EAEC(WT)} and Tle1^{EAEC(S197A)} proteins were obtained upon cleavage using the TEV protease (see inset in Fig. 2C). Since the two Tle1 family members characterized so far, *B. thailandensis* Tle1^{BT} and Tle1^{PA}, have phospholipase A₂ (PLA₂) activity (Russell *et al.*, 2013; Hu *et al.*, 2014), the activity of the purified Tle1^{EAEC} and Tle1^{EAEC(S197A)} were tested on fluorogenic phospholipid substrates (Fig. 2C). Tle1^{EAEC} possesses both phospholipase A₁ (PLA₁) activity (specific activity (SA) = 1338 pmole.min⁻¹.mg⁻¹) and a 12.5 lower PLA₂ activity (SA = 107 pmole.min⁻¹.mg⁻¹). By contrast, the purified Tle1 protein has undetectable phospholipase C and triacylglycerol lipase activities (data not shown). The PLA₁ and PLA₂ activities were abolished when the putative catalytic Ser-197 residue was substituted by an alanine (S197A mutant) (Fig. 2C). Finally, to gain insight into Tle1^{EAEC} specificity, the rate of hydrolysis of major lipids of bacterial membranes phosphatidylethanolamine (DLPE) and phosphatidylglycerol (DLPG), as well as phosphatidylcholine (DLPC) and phosphatidylserine (DLPS), was tested on monolayer films (Table 1). Tle1^{EAEC} – but not its S197A mutant – shows a slight activity on DLPC, DLPE and DLPS while DLPG hydrolysis was undetectable. Based on bioinformatic analyses and biochemical results, we conclude that the EC042_4534 protein is a member of the Tle1 family of T6SS effectors having PLA₁/PLA₂ activity.

In order to test whether Tle1^{EAEC} was involved in the anti-bacterial activity of the Sci-1 T6SS, we constructed a *tle1* deletion mutant strain. Due to technical genetic constraints (see Experimental Procedures), this strain is also deleted of the following *tli1* gene (that encodes its cognate immunity, see below). The Hcp release assay, which reflects proper assembly and function of the T6SS, demonstrated that Tle1 (and Tli1) is not necessary for T6SS assembly and function (Fig S1). However, as shown in Fig. 2D, the absence of Tle1 and Tli1 decreased the anti-bacterial activity of EAEC

against *E. coli* K-12 cells to the same extent as the T6SS-1 deletion mutant. The anti-bacterial activity was restored by the *trans*-expression of wild-type *tle1*, but not with that of *tle1*^{S197A} (Fig. 2D). Therefore these results suggest that the anti-bacterial toxicity of the *sci-1* T6SS gene cluster towards *E. coli* is conferred by the phospholipase activity of Tle1^{EAEC}.

Tli1^{EAEC} (EC042_4535) assures self-protection by inhibiting Tle1^{EAEC} phospholipase activity.

In T6SS, protection against kin cells is secured by the production of immunity proteins that specifically bind and inhibit their cognate toxins. Usually, effector/immunity genes are found in tandem in genomes. In the *sci-1* gene cluster, the *tle1*^{EAEC} gene is followed by a duplicated region encoding two putative immunity proteins: *EC042_4535* and *EC042_4536* (GIs: 284924256 and 284924257 respectively). In the sequenced 042 strain, the 225-amino-acid *EC042_4535* and *EC042_4536* proteins only differ by a few residues at their extreme C-termini (Fig. S2A). However, in the 17-2 strain used in this study, the *EC042_4536* gene has a frameshift mutation at nucleotide 386 that yields a 154-amino-acid truncated protein (Fig. S2A and S2B) that was not further analysed. To test if the product of the *EC042_4535* gene assures protection against Tle1^{EAEC}, the *EC042_4535* gene was expressed from the pBAD18 vector in W3110 *gfp*⁺ reporter prey cells. Anti-bacterial competition experiments showed that the production of *EC042_4535* in the *E. coli* K-12 prey conferred full protection against the anti-bacterial activity of the *Sci-1* T6SS (Fig. 3A). In addition to showing that *EC042_4535* confers protection, this result also demonstrates that Tle1^{EAEC} is delivered into target cells and suggests that Tle1^{EAEC} is the major anti-bacterial *Sci-1* T6SS effector in these conditions. In agreement with this result, when used as prey, the $\Delta EC042_4535-4536$ mutant was killed by the wild-type EAEC but not by the $\Delta T6SS-1$ or the *tle1-tli1* deletion mutant strain (Fig. 3B). Finally, production of *EC042_4535* in $\Delta EC042_4535-4536$ prey cells protected them against EAEC

killing. It is worthy to note that the recovered fluorescence of complemented $\Delta EC042_4535-4536$ cells is higher than in non complemented cells, likely due to the sickness of the $\Delta EC042_4535-4536$ prey cells (Fig. 3B). To confirm this result biochemically, the EC042_4535 protein was purified to homogeneity and tested for its ability to interfere with the Tle1^{EAEC} activity. Fig. 3C and Table 1 show that the Tle1^{EAEC} phospholipase activity was inhibited by EC042_4535 in a dose-dependent manner. Interestingly, the Tle1^{EAEC} activity was completely abolished with a Tle1^{EAEC}:EC042_4535 molecular ratio of 1:1 (Fig 3C), which is the highest ratio that can be expected between an enzyme and a specific inhibitor. Taken together, these results confirm that EC042_4535 is an immunity protein that protects against the phospholipase activity of Tle1^{EAEC}, and therefore EC042_4535 was named Tli1^{EAEC}.

Tli1^{EAEC}-dependent Tle1^{EAEC} inhibition is mediated by tight binding of Tli1^{EAEC} to Tle1^{EAEC}.

The Tli1^{EAEC}-mediated inhibition of Tle1^{EAEC} activity strongly suggests that Tli1^{EAEC} binds to Tle1^{EAEC}. To test this hypothesis, we first performed a bacterial two-hybrid (BACTH) assay. The Tle1^{EAEC} coding sequence was cloned downstream the T18 or T25 domains of the *Bordetella* adenylate cyclase, whereas the Tli1^{EAEC} coding sequence (deleted of its lipoprotein signal sequence) was cloned upstream the T18 and T25 domains. When the Tle1^{EAEC} and Tli1^{EAEC} fusion proteins were co-produced, the expression of the reporter gene was activated demonstrating that Tli1^{EAEC} and Tle1^{EAEC} interact (Fig. 4A). The BACTH assay also suggested that Tle1^{EAEC} and Tli1^{EAEC} are monomeric as no Tle1-Tle1 or Tli1-Tli1 interactions were detected (Fig. 4A). To validate these results by alternative approaches, the purified Tle1^{EAEC} and Tli1^{EAEC} proteins, and the mixture of the two purified proteins, were subjected to gel filtration and on-line multi-angle laser light scattering/quasi-elastic light scattering/absorbance/refractive index (MALS/QELS/UV/RI). Size

exclusion chromatography demonstrated that Tle1^{EAEC} and Tli1^{EAEC} have apparent molecular masses of 66 kDa and 23.9 kDa, respectively (Fig. 4B). These values, in agreement with their theoretical molecular weights of 62.3 and 24 kDa, further indicate that these proteins are monomeric in solution. Analysis of the Tle1^{EAEC}/Tli1^{EAEC} mixture showed the apparition of an additional peak containing both proteins (peak 1, Fig. 4B), demonstrating complex formation between the two proteins *in vitro*. With an apparent molecular mass of ~ 82 kDa, this complex likely corresponds to a Tle1^{EAEC}-Tli1^{EAEC} heterodimer (calculated molecular weight: 86 kDa). Analyses of purified Tle1^{EAEC}, Tli1^{EAEC} and Tle1^{EAEC}-Tli1^{EAEC} complex by MALS/QELS/UV/RI confirmed that both Tle1^{EAEC} and Tli1^{EAEC} are monomeric and that the Tle1^{EAEC}-Tli1^{EAEC} complex has a 1:1 stoichiometry (Fig. 4C). To determine the strength of the Tle1^{EAEC}-Tli1^{EAEC} interaction, the association of the two partners was monitored by Biolayer Interferometry (BLI). The Tli1^{EAEC} protein was biotinylated, coupled to a streptavidin sensortip and the association and dissociation of Tle1^{EAEC} were recorded for 600 sec. and 1,800 sec. respectively (Fig. 4D). Based on the curve fitting and assuming a 1:1 Tle1^{EAEC}:Tli1^{EAEC} heterodimer, Tle1^{EAEC} and Tli1^{EAEC} associates with a K_D constant value of 1.5 ± 0.05 nM. The K_{on} and K_{off} values ($K_{on}=1.65 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ and $K_{off}=2.2 \times 10^{-4} \text{ s}^{-1}$) are in agreement with a rapid association of the two proteins, but a slow dissociation of the complex. Taken together, these results demonstrate that Tle1^{EAEC} and Tli1^{EAEC} are monomeric in solution and interact to form a stable 1:1 heterodimer with nanomolar affinity.

Tli1^{EAEC} is an outer membrane lipoprotein protecting against delivery of cytoplasmic Tle1^{EAEC} in the periplasm of target cells.

The *tle1^{EAEC}* gene is predicted to encode a 62.3-kDa cytoplasmic protein, with no predicted signal peptide or trans-membrane segment. Fractionation of EAEC cells producing Tle1^{EAEC} fused to

a C-terminal VSVG epitope (Tle1_{VSVG}) showed that Tle1^{EAEC} co-localizes with the EF-Tu cytoplasmic marker hence confirming its cytoplasmic localization (Fig. 5A). Tle1_{VSVG} was not detected in the supernatant fraction (data not shown). By contrast, the *tli1*^{EAEC} gene is predicted to encode a protein with a signal sequence bearing a characteristic lipobox motif, such as other Tli1 homologues (Fig. 5B). In agreement with this prediction, Tli1^{EAEC} processing was inhibited by the signal peptidase II (SPII) inhibitor globomycin (Fig. 5C). In Gram-negative bacteria, lipoprotein sorting is controlled by the Lol complex and the final localization of the lipoprotein follows the “+2 rule”, *i.e.*, depends on the residue immediately downstream the acylated cysteine (Zückert, 2014). In Tli1^{EAEC}, the +2 residue is an asparagine suggesting an outer membrane destination (Fig. 5B). To determine its sub-cellular localization, total membranes of *tli1*^{EAEC} cells producing a functional C-terminally FLAG-tagged Tli1^{EAEC} protein (Tli1_{FL}) were subjected to sedimentation density sucrose gradient separation. By comparison with the behaviour of control proteins in the sucrose gradient (the outer membrane porin OmpF and the inner membrane NADH oxidase), we concluded that Tli1^{EAEC} co-fractionates with outer membrane proteins (Fig. 5D). Taken together these experiments defined that Tle1^{EAEC} is a cytoplasmic protein whereas Tli1^{EAEC} is an outer membrane lipoprotein.

To explain the interaction between Tle1^{EAEC} and Tli1^{EAEC} despite their different localization, we predicted that Tle1^{EAEC} should be delivered into the periplasm of the target cell, and thus be a periplasmic-acting toxin. To test this hypothesis, we tested the effects of the heterologous production of Tle1^{EAEC} in the cytoplasm or periplasm of *E. coli* K-12. Tle1^{EAEC} was readily produced in the cytoplasm of *E. coli* without any toxic effect (Fig. 6A). By contrast, we did not succeed to construct a vector allowing the artificial periplasmic production of Tle1^{EAEC} by fusing the *tle1*^{EAEC}-coding sequence downstream the *ompA* signal sequence (sp-Tle1^{EAEC}). The construction was only obtained when the cloning steps were performed in cells producing Tli1^{EAEC} from the pBAD33 vector in the

presence of arabinose. Indeed, periplasmic targeting of Tle1^{EAEC} is highly toxic in the absence of arabinose (Fig. 6B). The sp-Tle1^{EAEC} toxicity is efficiently counteracted by the co-production of Tli1^{EAEC}. In agreement with the *in vitro* and *in vivo* studies (Fig. 2C and 2D), the periplasmic production of the Tle1^{EAEC} catalytic mutant Tle1^{S197A} had roughly no effect on cell viability (Fig. 6B), confirming that Tle1^{EAEC} bacterial toxicity is conferred by its catalytic activity.

Tle1^{EAEC} interacts with the VgrG1 C-terminal extension.

The cargo model proposes that independent effectors are secreted through direct or indirect (via adaptor proteins) interactions with VgrG, Hcp or PAAR protein components (Silverman *et al.*, 2013; Shneider *et al.*, 2013; Whitney *et al.*, 2014; Hachani *et al.*, 2014; Durand *et al.*, 2014; Alcoforado Diniz and Coulthurst, 2015; Unterweger *et al.*, 2015; Liang *et al.*, 2015). Bioinformatic analyses of *sci-I* genes of unknown function showed that no putative adaptor protein is encoded in this cluster. To gain insights into the secretion mechanism of Tle1^{EAEC}, we therefore tested direct pairwise interactions between Tle1^{EAEC} and the *sci-I*-encoded Hcp1, VgrG1, and PAAR proteins by bacterial two-hybrid. Tle1^{EAEC} was fused downstream or upstream the T25 domain whereas the Hcp1, VgrG1 and PAAR proteins were fused to the T18 domain. The results presented in Fig. 7A indicate that Tle1^{EAEC} interacts directly with VgrG1, but not with the Hcp1 or PAAR proteins. The Tle1^{EAEC} - VgrG1 interaction could not be detected with the T25-Tle1 fusion protein suggesting fusion to the N-terminus of Tle1^{EAEC} may causes a steric hindrance preventing complex formation. To validate these data biochemically, we tested the VgrG1-Tle1^{EAEC} interaction using a co-immunoprecipitation assay. To visualize direct interactions, the two proteins were produced into the *E. coli* K-12 heterologous host. Western-blot analyses of the eluted material showed that VSVG-tagged Tle1^{EAEC} specifically co-immunoprecipitated with FLAG-tagged VgrG1, but not with Hcp1_{FLAG} (Fig. 7B and Fig. S3). Taken

together, the BACTH and co-immunoprecipitation assays demonstrate that Tle1^{EAEC} interacts with VgrG1.

Computer predictions and structural characterization of VgrG proteins showed that these proteins resemble the gp27-gp5 spike of bacteriophages (Pukatzki *et al.*, 2007; Leiman *et al.*, 2009). In EAEC, VgrG1 carries an additional C-terminal domain (CTD) separated from the gp27-gp5 common core by a predicted coiled-coil region (Fig. 7C). To assess the importance of this domain for the VgrG1-Tle1^{EAEC} interaction we constructed VgrG truncated derivatives lacking this region (VgrG₁₋₆₁₅ lacking the CTD and VgrG₁₋₅₇₃ lacking both CTD and the predicted coiled-coil region). Co-immunoprecipitation and BACTH analyses showed that these truncations abolish Tle1^{EAEC} binding, suggesting that the VgrG1 C-terminal domain is necessary for the VgrG1-Tle1^{EAEC} interaction (Fig. 7B and 7D). Furthermore, this domain alone is sufficient to mediate the interaction with Tle1^{EAEC}, as shown by co-immunoprecipitation and BACTH experiments using the VgrG₅₇₄₋₈₄₁ and VgrG₆₁₆₋₈₄₁ derivatives (Fig. 7B and 7D). The VgrG1 CTD possesses a domain of unknown function of the DUF2345 family (amino-acid 609-765). DUF2345 domains are commonly found associated with T6SS VgrG proteins (Boyer *et al.*, 2009). Further bioinformatic analyses of this CTD using fold recognition servers such as Phyre2 and HHPred predicted that VgrG1 CTD amino-acid 611-766 region is constituted of a regular repetition of small short-strands that are reminiscent to the C-terminal domain of gp5 and likely extends the VgrG spike. This additional β -prism domain is followed by a 62-amino-acid region (residues 780 to 841) predicted to fold as a transthyretin (TTR)-like domain. To test the contribution of this domain to the VgrG1-Tle1^{EAEC} interaction, we constructed a VgrG1 truncated variant lacking the TTR-like region (VgrG₁₋₇₇₈). Fig. 7D shows that VgrG₁₋₇₇₈ interaction with Tle1^{EAEC} is undetectable by BACTH analysis. However, VgrG₁₋₇₇₈ weakly interacts with Tle1^{EAEC} using the co-immunoprecipitation assay (Fig. 7B) suggesting that the absence

of the TTR domain strongly affects but not completely abolishes the interaction with Tle1^{EAEC}. Further BACTH experiments suggest that this domain is sufficient to mediate the interaction with Tle1^{EAEC} as the VgrG₇₇₁₋₈₄₁/Tle1^{EAEC} combination activates the expression of the reporter gene (Fig. 7D). Attempts to confirm by co-immunoprecipitation that the TTR domain of VgrG1 is sufficient for this interaction was unsuccessful, as this truncated variant was undetectable by Western blot (data not shown). Collectively, these results show (i) that the VgrG1 CTD is necessary and sufficient for the interaction with Tle1^{EAEC}, (ii) that the TTR domain of VgrG1 CTD is involved in the interaction but (iii) that a second interaction motif located within the 615-778 DUF2345 region stabilizes the VgrG1-Tle1 interaction.

To further test the importance of these interaction motifs for the delivery of Tle1^{EAEC}, we tested the ability of the VgrG1 C-terminal truncated derivatives to complement a *vgrG1* knock-out mutant in Hcp secretion and killing assays (Fig. 8). The co-production of full length VgrG1 and Tle1 complemented the killing defect of the *vgrG* knock-out strain (Fig. 8A). By contrast, production of the truncated VgrG₁₋₆₁₅ or VgrG₁₋₇₇₈ variants (with or without the co-production of Tle1) did not restore killing (Fig. 8A). However, this result is not due to the assembly of a non-functional T6S apparatus as deletion of the VgrG1 CTD did not affect Hcp release (Fig. 8B). Taken together, these results showed that deletion of the Tle1-binding motif within VgrG1 does not impair T6SS assembly but abolishes killing of prey cells, hence supporting the idea that Tle1 interaction with the C-terminal extension of VgrG is required for Tle1 export into target cells.

Discussion

In this study we show that the EAEC Sci-1 T6SS is required for inter-bacterial competition and report the full characterization of EC042_4534, the first T6SS toxin to be identified in EAEC, and

EC042_4535, its cognate immunity protein. We demonstrate that EC042_4534 has phospholipase A activity, belongs to family 1 of the T6SS lipase effectors (Russell *et al.*, 2013), and was therefore named Tle1^{EAEC}. A number of Tle proteins, delivered by the T6SS have been recently identified on the basis of their vicinity to *vgrG* genes. They consist of different enzymes divided into five divergent families (Russel *et al.*, 2013). Tle families 1-4 contain a characteristic GX SXG esterase motif found in lipases and some phospholipases. *In vitro* studies have shown that the *Burkholderia thailandensis* Tle1^{BT} and *P. aeruginosa* Tle1^{PA} effectors have PLA₂ activity (Russel *et al.*, 2013; Hu *et al.*, 2014). By contrast, the *Vibrio cholerae* Tle2^{VC} toxin carries PLA₁ activity (Russel *et al.*, 2013). No enzymatic activity has been assigned so far for members of the Tle3 and Tle4 families. Tle5 family members contain a duplicated HXDXXXXG motif characteristic of phospholipase D (PLD) superfamily, and can be divided in two subfamilies (Tle5a and Tle5b), with Tle5a being eukaryotic-like PLD (Russel *et al.*, 2013; Jiang *et al.*, 2014; Egan *et al.*, 2015; Spencer and Brown, 2015). The PLD activities of *P. aeruginosa* Tle5a^{PA} (known as PldA) and Tle5b^{PA} (known as PldB) have been demonstrated (Russel *et al.*, 2013; Jiang *et al.*, 2014, Spencer and Brown, 2015), while *Klebsiella pneumoniae* Tle5b^{KP} T6SS toxin presents a cardiolipin synthase activity (Lery *et al.*, 2014).

Our analyses showed that Tle1^{EAEC} has PLA₁ and to a lesser extent PLA₂ activity, which contrasts with the previously characterized Tle1 members, Tle1^{BT} and Tle1^{PA}, which have PLA₂ activity only (Russel *et al.*, 2013; Hu *et al.*, 2014). It is noteworthy that the Tle classification was built on their protein sequences and phylogenetic distribution, and not on their activity. It remains possible that Tle1 members may not have all the same selectivity for the sn-1 and sn-2 positions. Tle1 toxins consist to very heterologous proteins in terms of size (~ 500-900 residues). They all possess a DUF2235 (α/β hydrolase fold domain) likely forming the catalytic module but bear distinct additional domains. For example, Tle1^{PA} has a putative C-terminal membrane-anchoring module (Hu *et al.*,

2014) that has been shown to be critical for the catalytic activity, suggesting that the activity of Tle1 proteins might also be regulated by these additional domains. Further biochemical and structural characterizations of Tle1^{EAEC} and other Tle1 proteins are therefore required to better understand the differences in substrate selectivity on the phospholipid sn-1 and sn-2 moieties.

Our results also showed that Tle1^{EAEC} is required for the anti-bacterial activity conferred by the Sci-1 T6SS. Tle1^{BT} and Tle4^{APEC} were previously shown to be required for the anti-bacterial activity of *B. thailandensis* and avian pathogenic *Escherichia coli*, respectively (Russel *et al.*, 2013; Ma *et al.*, 2014). By contrast, Tle5a^{PA} (PldA) and Tle5b^{PA} (PldB) are required for both bacterial competition and virulence (Jiang *et al.*, 2014). Tle5b^{PA} delivery into eukaryotic host cells promotes invasion through the activation of the AKT/PI3pathway (Jiang *et al.*, 2014). Similarly, the Tle2^{VC} toxin is necessary for the anti-bacterial activity of *V. cholerae* and its ability to escape amoeba predation (Dong *et al.*, 2013). In *K. pneumonia*, Tle5^{KP} is required for full virulence in a mouse model of infection (Lery *et al.*, 2014). Although we did not observe any effect of the Sci-1 T6SS on *C. elegans* viability, we cannot rule out that the Tle1^{EAEC} toxin might be delivered into eukaryotic host cells to create damages. It would be interesting to test the role of the Sci-1 T6SS and of its specific Tle1^{EAEC} toxin on epithelial intestinal cells.

Our results also demonstrated that the production of Tle1^{EAEC} in the cytoplasm of *E. coli* K-12 has no effect on its viability. By contrast, cells do not survive when Tle1^{EAEC} is exported to the periplasm. This result is consistent with the observations that the heterologous periplasmic production of Tle1^{PA}, Tle5a^{PA} and Tle5b^{PA} is toxic (Jiang *et al.*, 2014; Hu *et al.*, 2014). One may hypothesize that (i) Tle1^{EAEC} targets specific lipids found in the outer leaflet of the inner membrane or in the inner leaflet of the outer membrane and/or (ii) that dedicated periplasmic proteins are required to activate

Tle1^{EAEC}, as previously shown for the colicin M toxin (Hullmann *et al.*, 2008). The activity of Tle toxins in the periplasm is in agreement with the synthesis of a cognate immunity protein called Tli that are usually periplasmic soluble proteins or membrane-anchored lipoprotein (Russel *et al.*, 2013). In this work, we have shown that Tli1^{EAEC} (EC042_4535) confers protection against Tle1^{EAEC}. Fractionation, isopycnic centrifugation and processing inhibition assays demonstrated that Tli1^{EAEC} is an outer membrane lipoprotein. Tli1^{EAEC}-mediated inhibition of Tle1^{EAEC} occurs by protein-protein contacts and is very efficient, as a molecular ratio of 1:1 totally abolishes Tle1^{EAEC} phospholipase activity. The interaction between the two partners was observed *in vivo* by bacterial two-hybrid analyses and biochemical approaches. Other immunities to phospholipases characterized so far have been shown to inhibit the action of the effector by direct protein-protein contacts, such as the *P. aeruginosa* Tle5/Tli5 pairs (Russell *et al.*, 2013; Jiang *et al.*, 2014). *In vitro* analyses of the purified Tle1^{EAEC}/Tli1^{EAEC} complex by gel filtration, MALS/QELS/UV/RI and biolayer interferometry collectively demonstrated that Tle1^{EAEC} interacts with Tli1^{EAEC} with a 1:1 stoichiometry and a K_D of 1.5 nM. This tight binding, with a very fast association and a very slow dissociation is in accordance with the role of Tli1^{EAEC} as a specific immunity protein, as the control of Tle1^{EAEC} activity should be strict among bacteria from the same species and should occur rapidly after delivery of Tle1^{EAEC}. This nanomolar affinity is in the same range as other T6SS effector/immunity pairs such as Tae1/Tai1 couples (Ding *et al.*, 2012; Shang *et al.*, 2012) and suggests an extensive surface of contact between the two partners. Indeed, the crystal structure of the putative *P. aeruginosa* Tle4 effector in complex with its putative immunity protein (Tli4^{PA}) revealed that Tli4^{PA} covers a surface area of $\sim 2,800 \text{ \AA}^2$ and use a grasp mechanism to prevent the interfacial activation of Tle4^{PA} (Lu *et al.*, 2014). Further structural characterization of the EAEC Tle1/Tli1 complex is required to better understand the molecular bases for this efficient inhibition.

In this work, we also addressed the secretion mechanism of Tle1^{EAEC}. Several mechanisms have been identified or proposed for independent effectors, and all of them involve direct or indirect contacts with the Hcp rings, the VgrG spike or the PAAR protein that sits on VgrG (Silverman *et al.*, 2013; Shneider *et al.*, 2013; Whitney *et al.*, 2014; Hachani *et al.*, 2014; Durand *et al.*, 2014). Recently, conserved adaptor proteins of the DUF4123 family interacting with both VgrG and the effector were shown to be required for the translocation of a number of T6SS effectors (Liang *et al.*, 2015; Unterweger *et al.*, 2015). Here, co-immunoprecipitation and bacterial two-hybrid analyses demonstrated that Tle1^{EAEC} interacts directly with VgrG1 and that this interaction is required for proper Tle1^{EAEC} delivery. A gene encoding a putative PAAR protein, *EC042_4537*, is found immediately downstream Tli1. However, PAAR is not required for the VgrG1/Tle1^{EAEC} direct interaction, suggesting that it constitutes a structural element at the tip of the VgrG spike or that it is involved in the recruitment and transport of a yet unidentified effector. In the cargo transport hypothesis, the VgrG proteins are used as carriers to deliver effectors into the target cell (Durand *et al.*, 2014). In *P. aeruginosa*, several toxins have been shown to be dependent on dedicated VgrG proteins for their delivery suggesting that VgrG proteins bear specific sequences to select cognate effectors (Whitney *et al.*, 2014; Hachani *et al.*, 2014). Our results support this idea as we found that the C-terminal extension of VgrG1 is necessary and sufficient to mediate binding to and transport of Tle1^{EAEC}. Particularly, we identified a region of 62 amino-acids at the C-terminus of VgrG1 involved in this interaction. This short domain is predicted to fold as a transthyretin-like (TTR) domain. TTR domains are putative protein-protein interaction modules. Interestingly, TTR domains were previously identified as PAAR protein extensions, and were proposed to be adaptors to mediate interaction with effector proteins (Shneider *et al.*, 2013). However, deletion of the TTR domain of VgrG1 did not totally abolish the interaction with Tle1^{EAEC}, suggesting that another motif may be present in the DUF2345 domain of VgrG1. Collectively, these results demonstrate that

DUF2345/TTR domains are involved in selection and transport of T6SS effectors. One may hypothesize that distinct motifs should be involved in the recruitment of effectors to confer specificity. Indeed, although this needs to be experimentally verified, a disordered loop within the C-terminal β -helix of the *E. coli* O157 VgrG1 protein was proposed to be an interaction site with effectors (Uchida *et al.*, 2014). Similarly, the recent release of the structure of the *P. aeruginosa* VgrG1 spike (PDB: 4MTK) reveals the existence of a small C-terminal helix that folds along the VgrG β -helix. We therefore propose that additional C-terminal domains in VgrG and likely on PAAR proteins might be considered as internal adaptors for interaction with effectors and that the EAEC VgrG1 DUF2345/TTR domain represents such a motif. Further experiments on different T6SS effectors will likely highlight the diversity of these selection modules.

Experimental Procedures

Bacterial strains, growth conditions and chemicals

The *E. coli* strains and plasmids used in this study are listed in Supplemental Table S1. The entero-aggregative *E. coli* EAEC strain 17-2 and its $\Delta T6SS-1$, $\Delta tle1-tli1$, $\Delta tli1-tli1b$ isogenic derivatives were used for this study. *E. coli* K-12 DH5 α , W3110, BTH101, and T7-Iq pLys strains were used for cloning steps, co-immunoprecipitation, bacterial two-hybrid and protein purification respectively. The *E. coli* K-12 W3110 strain carrying the pUA66-*rrnB* plasmid (*gfp* under the control of the constitutive *rrnB* ribosomal promoter, specifying strong and constitutive fluorescence, and kanamycin resistance (Zaslaver *et al.*, 2006)) was used as prey in antibacterial competition experiments. Strains were routinely grown in LB rich medium (or Terrific broth medium for protein purification) or in Sci-1 inducing medium (SIM; M9 minimal medium, glycerol 0.2%, vitamin B1 1 μ g/ml, casaminoacids 100 μ g/ml, LB 10%, supplemented or not with bactoagar 1.5%) with shaking at 37°C. Nematode

growth plates (NGM) were used for the *C. elegans* infection assay. Plasmids were maintained by the addition of ampicillin (100 µg/mL for *E. coli* K-12, 200 µg/mL for EAEC), kanamycin (50 µg/mL) or chloramphenicol (30 µg/mL). Expression of genes from pBAD, pOK12 and pASK-IBA vectors was induced at exponential phase for one hour with 0.1% of L-arabinose (Sigma-Aldrich), 100 µM of isopropyl--D-thio-galactopyranoside (IPTG, Eurobio) and 0.1 µg/mL of anhydrotetracyclin (AHT, IBA Technologies) respectively. 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-Gal, Eurobio) was used at 40 µg/mL. Globomycin (a kind gift of Dr. Danièle Cavard) was used at 50 µg/mL. Oligonucleotides and plasmids used in this study are listed in Supplemental Table S1.

Strain construction

The *tle1* (EC042_4534) and *tli1* (EC042_4535) genes were deleted into the EAEC 17-2 wild-type strain using a modified one-step inactivation procedure (Datsenko *et al.*, 2000) as previously described (Aschtgen *et al.*, 2008) using oligonucleotide pairs DEL-4534-5-DW/DEL-4534-3-DW. This oligonucleotide pairs carry 50-nucleotide 5' extensions homologous to regions adjacent to *tle1*. Because *tli1* is duplicated (*tli1b* has the same 5' sequence than *tli1*), attempts to delete *tle1* only yielded to the deletion of both *tle1* and *tli1* genes ($\Delta tle1-tli1$). The *tli1* (EC042_4535) and *tli1b* (EC042_4536) genes were deleted into 17-2 wild-type strain as described above using oligonucleotide pairs DEL-4535-5-DW/DEL-4535-3-DW. Kanamycin resistant clones were selected and verified by colony-PCR. The kanamycin cassette was then excised using plasmid pCP20. The deletions of the gene of interest were confirmed by colony-PCR and complementation studies.

Plasmid construction

Custom oligonucleotides were synthesized by Sigma Aldrich and are listed in Supplemental Table S1. EAEC *E. coli* 17-2 chromosomal DNA was used as a template for all PCRs. *E. coli* strain DH5 was used for cloning procedures. Polymerase Chain Reactions (PCR) were performed using a Biometra thermocycler using the Q5 High fidelity DNA polymerase (New England Biolabs). All the plasmids (except pETG20A and pOK12 derivatives) have been constructed by restriction-free cloning (van den Ent and Löwe, 2006) as previously described (Aschtgen *et al.*, 2010a). Briefly, genes of interest were amplified with oligonucleotides introducing extensions annealing to the target vector. The double-stranded product of the first PCR has then been used as oligonucleotides for a second PCR using the target vector as template. For the pETG20A-Tle1 and pETG20A-Tli1 constructs, the genes encoding Tle1^{EAEC} and signal sequence-less Tli1^{EAEC} were amplified by PCR using specific Gateway® primers containing *attB* sequences, which allow insertion into the pDONR201 cloning vector by the BP recombination reaction, and then introduced into the pETG20A vector. The final constructs allow the production of Tle1^{EAEC} or Tli1^{EAEC} fused to an N-terminal hexahistidine-tagged thioredoxin (TRX) followed by a Tobacco etch virus (TEV) protease cleavage site. For pOK-Tli_HA, pOK-VgrG_F, pOK-VgrG_{1-573F} and pOK-VgrG_{1-615F}, the coding sequence of *tli*, *vgrG* and the different *vgrG* domains were amplified by PCR using oligonucleotides introducing *EcoRI* and *XhoI* restriction sites and cloned into the pOK12-derivative vector pMS600 (Aschtgen *et al.*, 2008) digested by the same enzymes. In addition, the 3' oligonucleotide contains the sequence encoding the FLAG epitope, allowing C-terminal in-frame fusion of the *vgrG* derivatives with the FLAG epitope. The Ser197-to-Ala substitution was introduced in the pETG20A-Tle1, pBAD-Tle1-Tli1 and the pIBA-sp-Tle1 plasmids by QuickChange PCR-based targeted mutagenesis (Supplemental Table S1). Mutations were confirmed by DNA sequencing (GATC Biotech or Eurofins).

Caenorhabditis elegans infection assay

Virulence towards *C. elegans* was tested by a slow killing assay. L4 to adult stage nematods grown on *E. coli* OP50 were placed on unseeded NGM plates for 24 hours at 25°C. Twenty-five worms were then picked and placed onto lawns of bacteria to be tested. The viability of each individual was evaluated on a daily basis and the number of surviving nematods was plotted over time. The *E. coli* K-12 OP50 and *B. cenocepacia* K56-2 strains have been used as controls.

Interbacterial competition assay

The antibacterial growth competition assay was performed as described for the studies on the *Citrobacter rodentium* and EAEC Sci-2 T6SSs (Gueguen *et al.*, 2013; Brunet *et al.*, 2013) with modifications. The wild-type *E. coli* strain W3110 bearing the pUA66-*rrnB* plasmid (Kan^R (Zaslaver, 2006)) was used as prey in the competition assay. The pUA66-*rrnB* plasmid provides a strong constitutive green fluorescent (GFP⁺) phenotype. Attacker and prey cells were grown for 16 hours in SIM medium, and then diluted in SIM to allow maximal expression of the *sci-I* gene cluster (Brunet *et al.*, 2011). Once the culture reached an OD_{600nm} ~ 0.8, cells were harvested and normalized to an OD_{600nm} of 10 in SIM. Attacker and prey cells were mixed to a 4:1 ratio and 20-μl drops of the mixture were spotted in triplicate onto a pre-warmed dry SIM agar plate supplemented or not with arabinose 0.02% or IPTG 20 μM. After 4-hour incubation of the plates at 37°C, fluorescent images were recorded with a LI-COR Odyssey imager. The bacterial spots were scratched off, and cells were resuspended in LB medium supplemented with chloramphenicol and normalized to an OD_{600nm} of 0.5. Triplicates of 200 μl were transferred into wells of a black 96-well plate (Greiner) and the absorbance at 600 nm and fluorescence (excitation, 485 nm; emission, 530 nm) were measured with a Tecan Infinite M200 microplate reader. The relative fluorescence was expressed as the intensity of

fluorescence divided by the absorbance at 600 nm, after subtracting the values of a blank sample. These results are given in arbitrary units (AU) because the intensity of fluorescence is acquired with a variable gain and hence varies from one experiment to the other. For estimation of cfu, fluorescent Kan^R colonies were enumerated under UV light. The experiments were done in triplicate, with identical results, and we report here the results of a representative experiment.

Computer algorithms for phylogenetic analyses and Tle1^{EAEC} structure modelling

Phylogenetic tree reconstruction has been made using Phylogeny.fr (Dereeper *et al.*, 2008). The homology model of Tle1^{EAEC} was built with Coot (Emsley *et al.*, 2010) based on a Multalin alignment with the published *P. aeruginosa* effector Tle1^{PA} (PDB: 4O5P, Hu *et al.*, 2014). The regions present in Tle1^{EAEC} but not in 4O5P were not included in the modelling.

Bacterial two-hybrid assay (BACTH)

The adenylate cyclase-based bacterial two-hybrid technique (Karimova *et al.*, 1998) was used as previously published (Battesti and Bouveret, 2012). Briefly, pairs of proteins to be tested were fused to the isolated T18 and T25 catalytic domains of the *Bordetella* adenylate cyclase. After transformation of the two plasmids producing the fusion proteins into the reporter BTH101 strain, plates were incubated at 30°C for 48 hours. Three independent colonies for each transformation were inoculated into 600 µL of LB medium supplemented with ampicillin, kanamycin and IPTG (0.5 mM). After overnight growth at 30°C, 10 µL of each culture were dropped onto LB plates supplemented with ampicillin, kanamycin, IPTG and X-Gal and incubated for 16 hours at 30 °C. The experiments were done at least in triplicate and a representative result is shown.

Purification of Tle1, Tle1^{S197A} and Tli1

E. coli T7 lq pLys cells carrying the pETG20A-Tle1, pETG20A-Tle1^{S197A} or pETG20A-Tli1 plasmids were grown at 37°C in terrific broth to an OD₆₀₀ ~ 0.9 and *tle1*, *tle1*^{S197A} or *tli1* expression was induced with IPTG (0.5 mM) for 16 hours at 17°C. Cells were harvested by centrifugation and stored at -80°C. The cell pellet was resuspended in Tris-HCl 20 mM pH 8.0, NaCl 300 mM, glycerol 5% (v/v), lysozyme (0.25 mg/ml), DNase (2 µg/ml), MgSO₄ 20 mM, and phenylmethylsulfonyl fluoride (PMSF) 1 mM and cells were lysed by ultrasonication on ice. The insoluble material was discarded by centrifugation at 20,000 × *g* for 60 min at 4°C. The soluble thioredoxin 6×His-tagged Tle1, Tle1^{S197A} or Tli1 fusion proteins were purified by affinity chromatography on a nickel-nitrilotriacetic acid resin (Bio-Rad) and the tag was removed after dialysis by overnight hydrolysis with the TEV protease and reloading in presence of 10 mM imidazole. The proteins were further purified by gel filtration chromatography (Superdex 75, 10/30 GE Healthcare) equilibrated in Tris-HCl 20 mM pH 8.0, NaCl 300 mM, dithiothreitol (DTT) 2 mM using an AKTA purifier System (Amersham). The purified protein fractions were pooled and concentrated to ~15 mg/ml by ultrafiltration using the Amicon technology (Millipore, California, USA). For phospholipase activity assays, the purified Tle1 and Tle1^{S197A} proteins were concentrated to 0.6 mg/mL.

Purification of the Tle1^{EAEC}-Tli1^{EAEC} complex

Purified Tle1^{EAEC} and Tli^{EAEC} were mixed together in a molar ratio of 1:1.2. The complex was purified by gel filtration chromatography (Superdex 75, 10/30 GE Healthcare) equilibrated in a Tris-HCl 20 mM pH 8.0, NaCl 150 mM buffer using an AKTA purifier System (Amersham). The fractions containing the complex were pooled and concentrated to ~15 mg/mL as described above.

MALS/QELS/UV/RI-coupled size exclusion chromatography

Size exclusion chromatography (SEC) was performed on an Alliance 2695 HPLC system (Waters) using a pre-calibrated KW802.5 column (Shodex) run in Hepes 25 mM pH 7.3, NaCl 250 mM at 0.5 ml/min. MALS, UV spectrophotometry, QELS and RI were achieved with MiniDawn Treos (Wyatt Technology), a Photo Diode Array 2996 (Waters), a DynaPro (Wyatt Technology) and an Optilab rEX (Wyatt Technology), respectively, as described (Sciara *et al.*, 2008). Mass and hydrodynamic radius calculation was done with ASTRA software (Wyatt Technology) using a dn/dc value of 0.185 mL/g.

Biolayer interferometry (BLI)

The purified Tli1^{EAEC} protein was first biotinylated using the EZ-Link NHS-PEG4-Biotin kit (Perbio Science, France). The reaction was stopped by removing the excess of biotin using a Zeba Spin Desalting column (Perbio Science, France). BLI studies were performed in black 96-well plates (Greiner) at 25°C using an OctetRed96 (ForteBio, USA). Streptavidin biosensor tips (ForteBio, USA) were first hydrated with 0.2 mL Kinetic Buffer (KB, ForteBio, USA) for 20 min and then loaded with biotinylated Tli1^{EAEC} (10 g/mL in KB). The association of Tli1^{EAEC} with various concentrations of Tle1 (0.4 nM, 1 nM, 2.56 nM, 6.4 nM, 16 nM and 40 nM) was monitored for 600 sec, and the dissociation was followed for 1,800 sec in KB.

Phospholipase A₁ and A₂ fluorescent assays

Phospholipase activities of Tle1^{EAEC} and Tle1^{S197A} were performed using fluorogenic phospholipid

substrates. Phospholipase A₁ and A₂ activities were monitored continuously using BODIPY[®] dye-labeled phospholipids: PED-A₁ (N-((6-(2,4-DNP)Amino)Hexanoyl)-1-(BODIPY[®] FL C5)-2-Hexyl-*sn*-Glycero-3-Phosphoethanolamine) and red/green BODIPY[®] PC-A₂ (1-O-(6-BODIPY-[®]558/568-Aminoethyl)-2-BODIPY[®]FLC5-*sn*-Glycero-3-Phosphocholine), respectively (Darrow *et al.*, 2011; Farber *et al.*, 2001). The *sn*-2 fatty acyl group in PED-A₁ is a non-hydrolyzable alkyl chain, and PED-A₁ substrate was used to specifically measure the PLA₁ activity. The red/green BODIPY[®] PC-A₂ has a *sn*-1 uncleavable alkyl chain. Substrate stock solutions (50 μ M) were prepared in ethanol. All enzyme activities were assayed in Tris-HCl 10 mM pH 8.0, NaCl 150 mM, CaCl₂ 1 mM and Triton X-100 0.1%. Enzymatic reactions were performed at 20°C for 25 min in a final volume of 200 μ L containing 20 μ g of Tle1 purified protein (from a 0.6 mg.mL⁻¹ stock solution) and 5 μ M of the substrate. During pilot studies, we noted that concentrations of the purified Tle1 protein above 1mg.mL⁻¹ led to a decrease in the measured Tle1 PLA₁ specific activity. The release of BODIPY[®] (BFCL5) (Life Technologies) was recorded at λ_{exc} = 485 nm and λ_{em} = 538 nm using a 96-well plate fluorometer (Fluoroskan ascent, Thermoscientific). Enzymatic activities were quantified using a BFCL5 calibration curve (0.08 - 200 pmoles in activity buffers) and expressed in pmol of fatty acid (or BFLC5) released per minute per mg of protein (pmol min⁻¹ mg⁻¹). PLA₁ from *Thermomyces lanuginosus* and Bee venom PLA₂ (Sigma-Aldrich, Saint-Quentin Fallavier, France) were used as positive standards for PLA₁ and PLA₂ activities, respectively. Inhibition studies with Tli1^{EAEC} were performed by incubating 20 μ g of Tle1^{EAEC} with various molar ratio of Tli1^{EAEC} (x_i =0.125, 0.25, 0.5, 1 and 2). The residual activity was measured as described above.

Activities on phospholipid monolayer films

All experiments were performed using the KSV5000 system (KSV, Helsinki, Finland) equipped with

a Langmuir film balance to measure the surface pressure (Π) and monitored by the KSV Device Server Software v.3.50 running under Windows 7[®] as previously described (Point *et al.*, 2013). A Teflon “zero-order” trough (Verger and de Haas, 1973) was filled with Tris-HCl 10 mM pH 8.0, NaCl 100 mM, CaCl₂ 21 mM and EDTA 1 mM. The phospholipid monolayer was formed at the desired surface pressure (Π) of 20 mN.m⁻¹ by spreading a few microliters of a phospholipid solution (1 mg/mL in chloroform containing 0.4% v/v methanol) and further incubation for > 10 min (chloroform evaporation). Hydrolysis rate measurements were performed with a Teflon “zero-order” trough with two compartments: a reaction compartment (volume 43 mL; surface area, 38.5 cm²) and a reservoir compartment (volume 203 mL; surface area, 156.5 cm²) connected to each other by a small surface channel. The purified Tle1^{EAEC} protein was injected into the subphase of the reaction compartment only (11 nM enzyme final concentration), whereas the phospholipid lipid film spread at the air-water interface covers both of them. When using medium chain phospholipids, such as DLPC, DLPG, DLPS or DLPE, soluble lipolysis products are released upon the action of phospholipase and a drop in surface pressure can be recorded. Using the barostat mode available on the KSV5000 instrument, an automatically driven Teflon mobile barrier can be moved over the reservoir to compress the phospholipid film and compensate for the substrate molecules removed from the film by the enzyme hydrolysis, thus keeping the surface pressure constant (here at $\Pi = 20$ mN.m⁻¹). The kinetics of hydrolysis were recorded for at least 60 min and PLA activities (mol.cm⁻².min⁻¹.M⁻¹) were expressed as the number of moles of substrate hydrolyzed per time unit (min) and per surface unit (cm²) of the reaction compartment of the “zero-order” trough and for an arbitrary enzyme concentration of 1 M (de la Fournière *et al.*, 1994).

Globomycin treatment.

EAEC cells producing HA-tagged Tli1 from pOK- Tli1_{HA} were grown to an optical density at 600 nm (OD₆₀₀) of ~ 0.6 prior to the addition of 50 µg/mL of globomycin. After 10 min of treatment, IPTG was then added at a final concentration of 100 µM, and cells were further incubated for 30 min at 37°C. Cells were harvested, and samples were analyzed by SDS-PAGE and immunoblotting.

Escherichia coli K-12 toxicity assays

Cells were grown in LB at 37°C for 16 hours. Bacterial suspensions were normalized to an OD₆₀₀ of 2, serially diluted and 15 µL drops of each dilution were spotted onto selective LB agar plates containing or not arabinose 0.2%.

Co-immunoprecipitation experiments

One hundred mL of W3110 cells producing the proteins of interest from independent plasmids were grown to and OD₆₀₀ ~ 0.4 and the expression of the cloned genes was induced with IPTG 200 µM or arabinose 0.2% for one hour. The cells were harvested and the pellets were frozen in liquid nitrogen and stored at -80°C for 1 hour. Pellets were then resuspended in Tris-HCl 20 mM pH 8.0, NaCl 100 mM, sucrose 30%, lysozyme 100 µg/mL, EDTA 1 mM, DNase 100 µg/mL, RNase 100 µg/mL, Complete protease inhibitor cocktail (Roche) to an OD₆₀₀ ~ 100 and incubated on ice for 15 min. An equal volume of Tris-HCl 20 mM pH 8.0, NaCl 100 mM, MgCl₂ 5 mM was then added, and the cells were lysed by two passages at the French Press (800 psi). Lysates were clarified by centrifugation at 13,000 × g for 10 min. Supernatants were used for co-immunoprecipitation using Anti-FLAG[®] M2 affinity gel (Sigma-Aldrich). After 3 hours of incubation, the beads were washed twice with 1 mL of Tris-HCl 20 mM pH 8.0, NaCl 100 mM, sucrose 15%, and once with Tris-HCl 20 mM pH 8.0, NaCl

100 mM. Beads were recovered and resuspended in 25 μ L of SDS-loading buffer and heated for 10 min at 96°C prior to SDS-PAGE and Western-blot analyses.

Miscellaneous

Fractionation, sedimentation sucrose gradient assays, NADH oxidase activity measurements and Hcp release assay have been performed as previously described (Aschtgen *et al.*, 2008; Aschtgen *et al.*, 2010). SDS-Polyacrylamide gel electrophoresis was performed using standard protocols. For immunostaining, proteins were transferred onto 0.2 μ m nitrocellulose membranes (Amersham Protran), and immunoblots were probed with primary antibodies (see below) and goat secondary antibodies coupled to alkaline phosphatase and developed in alkaline buffer in presence of 5-bromo-4-chloro-3-indolylphosphate and nitroblue tetrazolium. The anti-TolB, anti-TolA, anti-OmpA and anti-OmpF polyclonal antibodies are from our laboratory collection, while the anti-HA (3F10 clone, Roche), anti-FLAG (M2 clone, Sigma Aldrich), anti-EF-Tu (Roche) and anti-VSVG (Sigma-Aldrich) monoclonal antibodies and alkaline phosphatase-conjugated goat anti-rabbit, mouse or rat secondary antibodies (Millipore) have been purchased as indicated.

Acknowledgments

We thank Jean-François Cavalier for phospholipid monolayer film experiments, Danièle Cavard for providing globomycin, Steve Garvis for help with the *Caenorhabditis elegans* model, Abir Benzeggouta for initial Tli1 constructs and Anant Kumar for constructing the pBAD-Hcp_{VSVG}. We thank Emmanuelle Bouveret, James Sturgis, Abdelrahim Zoued and the members of the Cascales,

Lloubès, Bouveret and Sturgis research groups for insightful discussions, Annick Brun, Isabelle Bringer and Olivier Uderso for technical assistance. Work in E.C. laboratory is supported by the Centre National de la Recherche Scientifique (CNRS), the Aix-Marseille Université and grants from the Agence Nationale de la Recherche (ANR-10-JCJC-1303-03, ANR-14-CE14-0006-02). Work in C.C. laboratory is supported by the CNRS, the Aix-Marseille Université and by grants from the Marseille-Nice Genopole, IBiSA and the Fondation de la Recherche Médicale (FRM DEQ2011-0421282). Ph.D studies of N.F., T.T.H.L. and V.S.N. are supported by the ANR-14-CE14-0006-02 grant, a fellowship from the University of Sciences and Techniques of Hanoi (USTH) and a fellowship from the French Embassy in Vietnam, respectively. M.S.A. was supported by a Ph.D fellowship from the French Ministry of Research.

REFERENCES

- Alcoforado Diniz, J., and Coulthurst, S.J. (2015) Intraspecies competition in *Serratia marcescens* is mediated by Type VI-secreted Rhs effectors and a conserved effector-associated accessory protein. *J Bacteriol.* **197**: 2350-60.
- Alcoforado Diniz, J., Liu, Y.C., Coulthurst, S.J. (2015) Molecular weaponry: diverse effectors delivered by the Type VI secretion system. *Cell Microbiol.* doi: 10.1111/cmi.12532.
- Aschtgen, M.S., Bernard, C.S., de Bentzmann, S., Lloubes, R., and Cascales, E. (2008) SciN is an outer membrane lipoprotein required for type VI secretion in enteroaggregative *Escherichia coli*. *J. Bacteriol.* **190**: 7523-7531.
- Aschtgen, M.S., Gavioli, M., Dessen, A., Lloubes, R., and Cascales, E. (2010) The SciZ protein

anchors the enteroaggregative *Escherichia coli* Type VI secretion system to the cell wall. *Mol. Microbiol.* **75**: 886-899.

Ballister, E.R., Lai, A.H., Zuckermann, R.N., Cheng, Y., and Mougous, J.D. (2008) In vitro self-assembly of tailorable nanotubes from a simple protein building block. *Proc. Natl. Acad. Sci. U. S. A.* **105**: 3733-3738.

Basler, M. (2015) Type VI secretion system: secretion by a contractile nanomachine. *Philos Trans R Soc Lond B Biol Sci* **370**: 20150021.

Basler, M., Pilhofer, M., Henderson, G.P., Jensen, G.J., and Mekalanos, J.J. (2012) Type VI secretion requires a dynamic contractile phage tail-like structure. *Nature* **483**: 182-186.

Battesti, A., and Bouveret, E. (2012) The bacterial two-hybrid system based on adenylate cyclase reconstitution in *Escherichia coli*. *Methods* **58**: 325-334.

Benz, J., and Meinhart, A. (2014) Antibacterial effector/immunity systems: it's just the tip of the iceberg. *Curr Opin Microbiol* **17**: 1-10.

Bonemann, G., Pietrosiuk, A., Diemand, A., Zentgraf, H., and Mogk, A. (2009) Remodelling of VipA/VipB tubules by ClpV-mediated threading is crucial for type VI protein secretion. *EMBO J.* **28**: 315-325.

Bonemann, G., Pietrosiuk, A., and Mogk, A. (2010) Tubules and donuts: a type VI secretion story. *Mol. Microbiol.* **76**: 815-821.

Boyer, F., Fichant, G., Berthod, J., Vandenbrouck, Y., and Attree, I. (2009) Dissecting the bacterial type VI secretion system by a genome wide in silico analysis: what can be learned from available

microbial genomic resources? *BMC Genomics* **10**: 104.

Brunet, Y.R., Bernard, C.S., Gavioli, M., Lloubes, R., and Cascales, E. (2011) An epigenetic switch involving overlapping fur and DNA methylation optimizes expression of a type VI secretion gene cluster. *PLoS Genet.* **7**: e1002205.

Brunet, Y.R., Espinosa, L., Harchouni, S., Mignot, T., and Cascales, E. (2013) Imaging type VI secretion-mediated bacterial killing. *Cell Rep.* **3**: 36-41.

Brunet, Y.R., Henin, J., Celia, H., and Cascales, E. (2014) Type VI secretion and bacteriophage tail tubes share a common assembly pathway. *EMBO Rep* **15**: 315-321.

Brunet, Y.R., Zoued, A., Boyer, F., Douzi, B., and Cascales, E. (2015) The Type VI secretion TssEFGK-VgrG phage-like baseplate is recruited to the TssJLM membrane complex via multiple contacts and serves as assembly platform for tail tube/sheath polymerization. *PLoS Genet.* **11**: e1005545.

Carruthers, M.D., Nicholson, P.A., Tracy, E.N., and Munson, R.S., Jr. (2013) *Acinetobacter baumannii* utilizes a type VI secretion system for bacterial competition. *PLoS One* **8**: e59388.

Cascales, E. (2008) The type VI secretion toolkit. *EMBO Rep.* **9**: 735-741.

Coulthurst, S.J. (2013) The Type VI secretion system - a widespread and versatile cell targeting system. *Res Microbiol* **164**: 640-654.

Darrow, A.L., Olson, M.W., Xin, H., Burke, S.L., Smith, C., Schalk-Hihi, C., *et al.* (2011) A novel fluorogenic substrate for the measurement of endothelial lipase activity. *J Lipid Res* **52**: 374-382.

Datsenko, K.A., and Wanner, B.L. (2000) One-step inactivation of chromosomal genes in *Escherichia*

coli K-12 using PCR products. *Proc. Natl. Acad. Sci. U.S.A.* **97**: 6640-6645.

de la Fournière, L., Ivanova, M.G., Blond, J.-P., Carrière, F., Verger, R. (1994) Surface behaviour of human pancreatic and gastric lipases. *Colloids Surf B.* **2**: 585-593.

Dereeper, A., Guignon, V., Blanc, G., Audic, S., Buffet, S., Chevenet, F., *et al.* (2008) Phylogeny.fr: robust phylogenetic analysis for the non-specialist. *Nucleic Acids Res.* **36**: W465-469.

Ding, J., Wang, W., Feng, H., Zhang, Y., and Wang, D.C. (2012) Structural insights into the *Pseudomonas aeruginosa* type VI virulence effector Tse1 bacteriolysis and self-protection mechanisms. *J Biol Chem* **287**: 26911-26920

Dong, T.G., Ho, B.T., Yoder-Himes, D.R., and Mekalanos, J.J. (2013) Identification of T6SS-dependent effector and immunity proteins by Tn-seq in *Vibrio cholerae*. *Proc Natl Acad Sci U S A* **110**: 2623-2628.

Douzi, B., Spinelli, S., Blangy, S., Roussel, A., Durand, E., Brunet, Y.R., *et al.* (2014) Crystal structure and self-interaction of the type VI secretion tail-tube protein from enteroaggregative *Escherichia coli*. *PLoS One* **9**: e86918.

Durand, E., Derrez, E., Audoly, G., Spinelli, S., Ortiz-Lombardia, M., Raoult, D., *et al.* (2012) Crystal structure of the VgrG1 actin cross-linking domain of the *Vibrio cholerae* type VI secretion system. *J Biol Chem* **287**: 38190-38199.

Durand, E., Cambillau, C., Cascales, E., and Journet, L. (2014) VgrG, Tae, Tle, and beyond: the versatile arsenal of Type VI secretion effectors. *Trends Microbiol* **22**: 498-507.

Durand, E., Nguyen, V.S., Zoued, A., Logger, L., Péhau-Arnaudet, G., Aschtgen, M.S., *et al.* (2015)

Biogenesis and structure of a type VI secretion membrane core complex. *Nature* **523**: 555-60.

Egan, F., Reen, F.J., and O'Gara, F. (2015) The distribution and diversity in metagenomic datasets reveal niche specialization. *Environ Microbiol Rep* **7**: 194-203.

Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* **66**: 486-501.

Farber, S.A., Pack, M., Ho, S.Y., Johnson, I.D., Wagner, D.S., Dosch, R., *et al.* (2001) Genetic analysis of digestive physiology using fluorescent phospholipid reporters. *Science* **292**: 1385-1388.

Finn, R.D., Clements, J., Eddy, S.R. (2011) HMMER web server: interactive sequence similarity searching. *Nucl Acids Res* **39**: W29-37.

Gueguen, E., and Cascales, E. (2013) Promoter swapping unveils the role of the *Citrobacter rodentium* CTS1 type VI secretion system in interbacterial competition. *Appl Environ Microbiol* **79**: 32-38.

Hachani, A., Allsopp, L.P., Oduko, Y., and Filloux, A. (2014) The VgrG proteins are "a la carte" delivery systems for bacterial type VI effectors. *J Biol Chem* **289**: 17872-17884.

Ho, B.T., Dong, T.G., and Mekalanos, J.J. (2014) A view to a kill: the bacterial type VI secretion system. *Cell Host Microbe* **15**: 9-21.

Hood, R.D., Singh, P., Hsu, F., Guvener, T., Carl, M.A., Trinidad, R.R., *et al.* (2010) A type VI secretion system of *Pseudomonas aeruginosa* targets a toxin to bacteria. *Cell Host Microbe* **7**: 25-37.

Hu, H., Zhang, H., Gao, Z., Wang, D., Liu, G., Xu, J., *et al.* (2014) Structure of the type VI secretion phospholipase effector Tle1 provides insight into its hydrolysis and membrane targeting. *Acta*

Crystallogr D Biol Crystallogr **70**: 2175-2185.

Hullmann, J., Patzer, S.I., Romer, C., Hantke, K., and Braun, V. (2008) Periplasmic chaperone FkpA is essential for imported colicin M toxicity. *Mol Microbiol* **69**: 926-937.

Jiang, F., Waterfield, N.R., Yang, J., Yang, G., and Jin, Q. (2014) A *Pseudomonas aeruginosa* type VI secretion phospholipase D effector targets both prokaryotic and eukaryotic cells. *Cell Host Microbe* **15**: 600-610.

Kapitein, N., Bonemann, G., Pietrosiuk, A., Seyffer, F., Hausser, I., Locker, J.K., and Mogk, A. (2013) ClpV recycles VipA/VipB tubules and prevents non-productive tubule formation to ensure efficient type VI protein secretion. *Mol. Microbiol.* **87**: 1013-1028.

Karimova, G., Pidoux, J., Ullmann, A., and Ladant, D. (1998) A bacterial two-hybrid system based on a reconstituted signal transduction pathway. *Proc. Natl. Acad. Sci. U.S.A.* **95**: 5752-5756.

Kelley, L.A., and Sternberg, M.J. (2009) Protein structure prediction on the Web: a case study using the Phyre server. *Nat Protoc* **4**: 363–371.

Kudryashev, M., Wang, R.Y., Brackmann, M., Scherer, S., Maier, T., Baker, D., *et al.* (2015) Structure of the type VI secretion system contractile sheath. *Cell* **160**: 952-62.

Leiman, P.G., Basler, M., Ramagopal, U.A., Bonanno, J.B., Sauder, J.M., Pukatzki, S., *et al.* (2009) Type VI secretion apparatus and phage tail-associated protein complexes share a common evolutionary origin. *Proc. Natl. Acad. Sci. U.S.A.* **106**: 4154-4159.

Lery, L.M., Frangeul, L., Tomas, A., Passet, V., Almeida, A.S., Bialek-Davenet, S., *et al.* (2014) Comparative analysis of *Klebsiella pneumoniae* genomes identifies a phospholipase D family protein

as a novel virulence factor. *BMC Biol* **12**: 41.

Liang, X., Moore, R., Wilton, M., Wong, M.J., Lam, L., and Dong, T.G. (2015) Identification of divergent type VI secretion effectors using a conserved chaperone domain. *Proc Natl Acad Sci U S A* **112**: 9106-9111

Lu, D., Zheng, Y., Liao, N., Wei, L., Xu, B., Liu, X., and Liu, J. (2014) The structural basis of the Tle4-Tli4 complex reveals the self-protection mechanism of H2-T6SS in *Pseudomonas aeruginosa*. *Acta Crystallogr D Biol Crystallogr* **70**: 3233-3243.

Ma, J., Bao, Y., Sun, M., Dong, W., Pan, Z., Zhang, W., Lu, C. and Yao, H. (2014) Two functional type VI secretion systems in avian pathogenic *Escherichia coli* are involved in different pathogenic pathways. *Infect Immun* **82**: 3867-3879

MacIntyre, D.L., Miyata, S.T., Kitaoka, M., and Pukatzki, S. (2010) The *Vibrio cholerae* type VI secretion system displays antimicrobial properties. *Proc Natl Acad Sci U S A* **107**: 19520-19524.

Mougous, J.D., Cuff, M.E., Raunser, S., Shen, A., Zhou, M., Gifford, C.A., *et al.* (2006) A virulence locus of *Pseudomonas aeruginosa* encodes a protein secretion apparatus. *Science* **312**: 1526-1530.

Murdoch, S.L., Trunk, K., English, G., Fritsch, M.J., Pourkarimi, E., and Coulthurst, S.J. (2011) The opportunistic pathogen *Serratia marcescens* utilizes type VI secretion to target bacterial competitors. *J Bacteriol* **193**: 6057-6069.

Pell, L.G., Kanelis, V., Donaldson, L.W., Howell, P.L., and Davidson, A.R. (2009) The phage lambda major tail protein structure reveals a common evolution for long-tailed phages and the type VI bacterial secretion system. *Proc. Natl. Acad. Sci. U.S.A.* **106**: 4160-4165.

- Point, V., Benarouche, A., Jemel, I., Parsiegla, G., Lambeau, G., Carriere, F., and Cavalier, J.F. (2013) Effects of the propeptide of group X secreted phospholipase A(2) on substrate specificity and interfacial activity on phospholipid monolayers. *Biochimie* **95**: 51-58.
- Pukatzki, S., Ma, A.T., Sturtevant, D., Krastins, B., Sarracino, D., Nelson, W.C., *et al.* (2006) Identification of a conserved bacterial protein secretion system in *Vibrio cholerae* using the *Dictyostelium* host model system. *Proc. Natl. Acad. Sci. U.S.A.* **103**: 1528-1533.
- Pukatzki, S., Ma, A.T., Revel, A.T., Sturtevant, D., and Mekalanos, J.J. (2007) Type VI secretion system translocates a phage tail spike-like protein into target cells where it cross-links actin. *Proc Natl Acad Sci U S A* **104**: 15508-15513.
- Russell, A.B., LeRoux, M., Hathazi, K., Agnello, D.M., Ishikawa, T., Wiggins, P.A., *et al.* (2013) Diverse type VI secretion phospholipases are functionally plastic antibacterial effectors. *Nature* **496**: 508-512.
- Russell, A.B., Peterson, S.B., and Mougous, J.D. (2014) Type VI secretion system effectors: poisons with a purpose. *Nat Rev Microbiol* **12**: 137-148.
- Schwarz, S., West, T.E., Boyer, F., Chiang, W.C., Carl, M.A., Hood, R.D., Rohmer, L., *et al.* (2010) Burkholderia Type VI Secretion Systems Have Distinct Roles in Eukaryotic and Bacterial Cell Interactions. *PLoS Pathog* **6**: e1001068.
- Sciara, G., Blangy, S., Siponen, M., Mc Grath, S., van Sinderen, D., Tegoni, M., *et al.* (2008) A topological model of the baseplate of lactococcal phage Tuc2009. *J. Biol. Chem.* **283**: 2716-2723.
- Shang, G., Liu, X., Lu, D., Zhang, J., Li, N., Zhu, C. *et al.* (2012) Structural insight into how *Pseudomonas aeruginosa* peptidoglycan hydrolase Tse1 and its immunity protein Tsi1 function.

Biochem J **448**: 201-211

Shneider, M.M., Buth, S.A., Ho, B.T., Basler, M., Mekalanos, J.J., and Leiman, P.G. (2013) PAAR-repeat proteins sharpen and diversify the type VI secretion system spike. *Nature* **500**: 350-353.

Silverman, J.M., Brunet, Y.R., Cascales, E., and Mougous, J.D. (2012) Structure and regulation of the type VI secretion system. *Annu. Rev. Microbiol.* **66**: 453-472.

Silverman, J.M., Agnello, D.M., Zheng, H., Andrews, B.T., Li, M., Catalano, C.E., Gonen, T., and Mougous, J.D. (2013) Haemolysin coregulated protein is an exported receptor and chaperone of type VI secretion substrates. *Mol Cell* **51**: 584-593.

Spencer, C., and Brown, H.A. (2015) Biochemical Characterization of a *Pseudomonas aeruginosa* Phospholipase D. *Biochemistry* **54**: 1208-1218.

Suarez, G., Sierra, J.C., Erova, T.E., Sha, J., Horneman, A.J., and Chopra, A.K. (2010) A type VI secretion system effector protein, VgrG1, from *Aeromonas hydrophila* that induces host cell toxicity by ADP ribosylation of actin. *J Bacteriol* **192**: 155-168.

Uchida, K., Leiman, P.G., Arisaka, F., and Kanamaru, S. (2014) Structure and properties of the C-terminal beta-helical domain of VgrG protein from *Escherichia coli* O157. *J Biochem* **155**: 173-182.

Unterweger, D., Kostiuk, B., Ötjengerdes, R., Wilton, A., Diaz-Satizabal, L. and Pukatzki, S. (2015) Chimeric adaptor proteins translocate diverse type VI secretion system effectors in *Vibrio cholerae*. *EMBO J.* **34**: 2198-2210.

van den Ent, F., and Lowe, J. (2006) RF cloning: a restriction-free method for inserting target genes into plasmids. *J. Biochem. Biophys. Methods* **67**: 67-74.

- Verger, R., and de Haas, G.H. (1973) Enzyme reactions in a membrane model. 1: A new technique to study enzyme reactions in monolayers. *Chem Phys Lipids* **10**: 127-136.
- Whitney, J.C., Beck, C.M., Goo, Y.A., Russell, A.B., Harding, B.N., De Leon, J.A., *et al.* (2014) Genetically distinct pathways guide effector export through the type VI secretion system. *Mol Microbiol* **92**: 529-542.
- Whitney, J.C, Quentin, D., Sawai, S., LeRoux, M, Harding, B.N, Ledvina, H.E. *et al.* (2015) An interbacterial NAD(P)(+) glycohydrolase toxin requires elongation factor Tu for delivery to target cells. *Cell* **163**: 607-619
- Zaslaver, A., Bren, A., Ronen, M., Itzkovitz, S., Kikoin, I., Shavit, S., *et al.* (2006) A comprehensive library of fluorescent transcriptional reporters for Escherichia coli. *Nat Methods* **3**: 623-628.
- Zoued, A., Brunet, Y.R., Durand, E., Aschtgen, M.S., Logger, L., Douzi, B., *et al.* (2014) Architecture and assembly of the Type VI secretion system. *Biochim Biophys Acta* **1843**: 1664-1673.
- Zuckert, W.R. (2014) Secretion of bacterial lipoproteins: through the cytoplasmic membrane, the periplasm and beyond. *Biochim Biophys Acta* **1843**: 1509-1516.

Table 1. Rates of hydrolysis of DLPC, DLPE, DLPS and DLPG monolayers at a constant surface pressure of 20 mN m⁻¹.

Phospholipid Substrates	enzyme activity ($\mu\text{mole cm}^{-2} \text{ min}^{-1} \text{ M}^{-1}$)		
	Tle1	Tle1 _{S197A}	Tle1 + Tli1 (1:2 mol/mol)
DLPC	148 ($\pm$ 9)	<i>no activity</i>	<i>no activity</i>
DLPE	109 ($\pm$ 5)	<i>no activity</i>	<i>no activity</i>
DLPS	97 ($\pm$ 4)	<i>no activity</i>	<i>no activity</i>
DLPG	<i>no activity</i>	<i>no activity</i>	<i>no activity</i>

Assays were carried out in a ‘zero order’ trough as described in the Experimental Procedures section. The final concentration of Tle1 and Tle1_{S197A} was 11 nM for the lipolysis of each phospholipid. Enzyme activities are expressed as the number of moles of substrate hydrolyzed by time unit and surface unit of the reaction compartment of the “zero order” trough for an arbitrary lipase concentration of 1 M. All data are presented as mean values $\pm$ standard deviations of at least 2 independent assays (CV% < 6%). Buffer: 10 mM Tris (pH 8.0), 100 mM NaCl, 21 mM CaCl₂ and 1 mM EDTA.

FIGURE LEGENDS

Figure 1. The *sci-1* T6SS gene cluster contributes to EAEC anti-bacterial activity. (A) The EAEC *sci-1* T6SS is not required for virulence towards the *C. elegans* model of infection. The number of nematods surviving on lawn of the indicated strain (closed squares, *E. coli* OP50; closed circles, EAEC 17-2; open circles, EAEC $\Delta T6SS-I$; closed triangles, *Burkholderia cenocepacia* K56-2) was plotted as percentage (% survival) over time (days). (B) Anti-bacterial assay. Prey cells (W3110 *gfp*⁺, kan^R) were mixed with the indicated attacker cells, spotted onto *sci-1*-inducing medium (SIM) agar plates and incubated for 4 hours at 37°C. The image of a representative bacterial spot is shown and the relative fluorescent levels (in arbitrary unit, AU) are indicated in the upper graph. The number of recovered *E. coli* prey cells is indicated in the lower graph (in log₁₀ of colony-forming units (cfu)). The circles indicate values from three independent assays, and the average is indicated by the bar.

Figure 2. EC042_4534 phospholipase activity is responsible for Sci-1-mediated antibacterial activity. (A) Schematic representation of the EAEC 17-2 *sci-1* T6SS gene cluster. The numbers on top refer to the genes locus tag (EC042_XXXX). Genes encoding core components (identified by their names on bottom) are colored grey. Genes of unknown function are indicated in white. The EC042_4534 gene encoding Tle1 is indicated in green whereas the two genes encoding the Tli1 and Tli1b immunity proteins are colored in blue. The asterisk below Tli1b indicates that a frameshift mutation on the 17-2 chromosome yields a truncated protein (Supplemental Fig. S2). (B) Homology-based structural model of EC042_4534 based on the crystal structure of the *P. aeruginosa* Tle1^{PA} effector (PDB: 4O5P). The magnification highlights the positions and orientations of the putative

catalytic triad amino-acid side chains (Ser-197, His-245 and Asp-310). (C) Specific phospholipase A₁ (PLA₁) and A₂ (PLA₂) activity measurements of the EC042_4534 Tle1^{EAEC} WT and S197A mutant proteins using fluorescent phospholipids. Specific activities were calculated from the velocity slope obtained for 25 minutes using 20 µg of purified protein. Data are expressed as mean values ± standard deviations of three independent assays (CV% < 5%). The SDS-PAGE analysis of the purified EC042_4534 (Tle1^{WT}) and S197A (Tle1^{S197A}) proteins (40 µg) after Coomassie blue staining is shown in the inset (molecular weight markers (in kDa) are indicated on the right). (D) EC042_4534 (Tle1^{EAEC}) phospholipase activity is responsible for Sci-1-mediated antibacterial activity. The antibacterial activity was assessed by mixing W3110 *gfp*⁺ prey cells with the indicated attacker cells for 4 hours at 37°C in *sci-1*-inducing medium containing 0.02 % arabinose (WT (EAEC 17-2), ΔT6SS-1 (*sci-1* gene cluster deletion derivative) and Δ*tle1-tli1* (17-2 deleted of the *tle1* and *tli1* genes) carrying the pBAD18 empty vector, or Δ*tle1-tli1* producing wild-type Tle1 (Tle1^{WT}) and Tli1 or the S197A Tle1 mutant (Tle1^{S197A}) and Tli1 from the pBAD18-Tle1-Tli1 or pBAD18-Tle1^{S197A}-Tli1, respectively). The image of a representative bacterial colony is shown and the relative fluorescent levels (in arbitrary units, AU) are indicated in the upper graph. The number of recovered *E. coli* prey cells is indicated in the lower graph (in log₁₀ of colony-forming units (cfu)). The circles indicate values from three independent assays, and the average is indicated by the bar.

Figure 3. Tli1^{EAEC} inhibits Tle1^{EAEC} anti-bacterial phospholipase activity. (A) Anti-bacterial assay. The anti-bacterial activity was assessed by mixing W3110 *gfp*⁺ prey cells producing (pBAD-Tli1^{EAEC}) or not (pBAD18) the EC042_4535 (Tli1^{EAEC}) protein from the pBAD promoter with the indicated attacker cells for 4 hours at 37°C in *sci-1*-inducing medium containing 0.02% arabinose. The image of a representative bacterial colony is shown and the relative fluorescent levels (in

arbitrary units, AU) are indicated in the upper graph. The number of recovered *E. coli* prey cells is indicated in the lower graph (in log₁₀ of colony-forming units (cfu)). The circles indicate values from three independent assays, and the average is indicated by the bar. **(B)** The anti-bacterial activity was assessed by mixing $\Delta tli1-tli1b$ (17-2 deleted of the *tli1* and *tli1b* genes) *gfp*⁺ prey cells producing (pBAD-Tli1^{EAEC}) or not (pBAD18) the EC042_4535 (Tli1^{EAEC}) protein from the pBAD promoter with the indicated attacker cells for 4 hours at 37°C in *sci-I*-inducing medium containing 0.02% arabinose. The image of a representative bacterial colony is shown and the relative fluorescent levels (in arbitrary units, AU) are indicated in the upper graph. The number of recovered *E. coli* prey cells is indicated in the lower graph (in log₁₀ of colony-forming units (cfu)). The circles indicate values from three independent assays, and the average is indicated by the bar. **(C)** Tli1^{EAEC} inhibition of Tle1^{EAEC} PLA₁ activity. The rate of hydrolysis of PED-A₁ by purified Tle1^{EAEC} at 20°C in presence of increasing concentrations of Tli1^{EAEC} was plotted against the molar excess of Tli1^{EAEC}. The SDS-PAGE analysis of the purified Tli1^{EAEC} (Tli1) protein after Coomassie blue staining is shown in the inset (molecular weight markers (in kDa) are indicated on the right).

Figure 4. Tli1^{EAEC} binds Tle1^{EAEC} with nanomolar affinity. **(A)** Bacterial two-hybrid analysis. BTH101 reporter cells producing the indicated Tle1^{EAEC} (Tle1) or Tli1^{EAEC} (Tli1) proteins fused to the T18 or T25 domain of the *Bordetella* adenylate cyclase were spotted on X-Gal indicator plates. The blue color of the colony reflects the interaction between the two proteins. Controls include T18 and T25 fusions to TolB and Pal, two proteins that interact but unrelated to the T6SS. **(B)** Gel filtration analysis on a calibrated Superdex 75 (10/30) column. The purified Tli1^{EAEC} (left panel), Tle1^{EAEC} (middle panel) proteins and the Tle1^{EAEC}/Tli1^{EAEC} mixture (right panel) were separated by gel filtration. Tli1^{EAEC}, Tle1^{EAEC} and the Tle1^{EAEC}-Tli1^{EAEC} complex eluted at 12.8 ml (~ 24 kDa),

10.37 ml (~ 66 kDa) and 9.8 ml (~ 82 kDa) respectively. The inset is the SDS-PAGE and Coomassie blue staining analysis of the fractions eluted after Tle1^{EAEC}-Tli1^{EAEC} complex separation. Peak 1 contains the two proteins whereas peak 2 (13.1 ml) contains the excess of Tli1^{EAEC}. The molecular weight markers (in kDa) are indicated on the right. **(C)** MALS/SEC/UV/RI analysis. The UV absorbance at 280 nm corresponding to Tli1^{EAEC} (blue line), Tle1^{EAEC} (orange line) and to the Tle1^{EAEC}-Tli1^{EAEC} complex (red line) was plotted against time (min. after sample injection in the High Performance Liquid Chromatography system). The traces indicating the molar mass (indicated on the left, in Da) are shown on each peak. **(D)** Bio-layer interferometry analysis. Recordings of the binding of purified Tle1^{EAEC} (concentrations (in nM) indicated above the corresponding curve) to the streptavidin chip coupled to biotinylated Tli1^{EAEC}. The response (in nm) is plotted versus the time (in sec.). The experimental association and dissociation curves (blue) are compared to the simulated ones (red). The calculated K_D value is 1.50 ± 0.05 nM.

Figure 5. Sub-cellular localizations of Tle1^{EAEC} and Tli1^{EAEC}. **(A)** Tle1^{EAEC} is a cytoplasmic protein. Total *Δtle1-tli1* cells producing VSVG-tagged Tle1^{EAEC} (Tle1_{VSVG}) (T) were fractionated to isolate the periplasmic (P), cytoplasmic (C) and membrane fractions (M). Proteins from 10⁹ (T, M) and 2×10⁹ (P, C) cells were separated by SDS-PAGE and immunodetected with anti-VSVG monoclonal (Tle1_{VSVG}), anti-EF-Tu (cytoplasmic marker), TolB (periplasmic marker), and TolA (membrane marker) antibodies. The position of the immunodetected proteins is indicated on the right. The molecular weight markers (in kDa) are indicated on the left. **(B)** Tli1^{EAEC} bears a characteristic lipobox motif. ClustalW (T-Coffee) sequence alignment of the N-terminal region of the Tli1^{EAEC} protein with that of representative homologous proteins (DUF2931 containing proteins) identified by HMMER analysis (Finn *et al.*, 2011). The putative lipobox motif (L-[G/A/S]-[G/A/S]-C) is indicated



by a blue box. The position of the N-terminal cysteine residue of the processed form is underlined in green. **(C)** Tli1^{EAEC} processing is dependent on signal peptidase II. EAEC $\Delta tli1-tli1b$ 2×10^9 cells producing HA-tagged Tli1^{EAEC} (Tli1_{HA}) treated (+) or not (-) with the signal peptidase II inhibitor antibiotic globomycin were subjected to SDS-PAGE and immunodetection with the anti-HA and anti-OmpA antibodies. The unprocessed form of Tli1_{HA} is indicated by an asterisk. The molecular weight markers (in kDa) are indicated on the left. **(D)** Tli1^{EAEC} is an outer membrane protein. Total membrane from $\Delta tli1-tli1b$ cells producing FLAG-tagged Tli1^{EAEC} (Tli1_{FL}) were separated on a discontinuous sedimentation sucrose gradient. The collected fractions were subjected to measurements of the NADH oxidase activity (inner membrane marker, represented as relative % to the total activity) (upper graph) and to SDS-PAGE and immunodetection with the anti-OmpF (outer membrane marker), anti-TolA (inner membrane marker) and anti-FLAG antibodies. The positions of outer and inner membrane fractions (based on control markers) are indicated.


Figure 6. Tle1^{EAEC} periplasmic toxicity is counteracted by Tli1^{EAEC}. **(A)** Cytoplasmic production of Tle1^{EAEC} is not toxic. Serial dilutions (from 0 to 10^{-7}) of normalized cultures of *E. coli* K-12 W3110 cells producing the wild-type (Tle1^{WT}) or the S197A mutant (Tle1^{S197A}) Tle1^{EAEC} proteins from the pBAD18 vector were spotted on LB agar plates supplemented (right panel) – or not (left panel) – with 0.2% arabinose. **(B)** Tli1^{EAEC} protects the cell against the toxicity of the periplasmic production of Tle1^{EAEC}. Serial dilutions (from 0 to 10^{-7}) of normalized cultures of *E. coli* K-12 W3110 cells producing Tli1^{EAEC} from the pBAD33 vector and the maltose-binding protein (MBP), the wild-type (Tle1^{WT}) or the S197A mutant (Tle1^{S197A}) proteins fused to a signal peptide (sp) from the pASK-IBA4 vector (periplasmic targeting) were spotted on LB agar plates supplemented (right panel) – or not (left panel) – with 0.2% arabinose.




Figure 7. Tle1^{EAEC} interacts with the VgrG1 C-terminal extension. (A) Tle1^{EAEC} interacts with VgrG, not with Hcp or PAAR. BTH101 reporter cells producing Tle1^{EAEC} fused to the T25 domain, and Hcp1, VgrG1 or PAAR proteins fused to the T18 domain of the *Bordetella* adenylate cyclase were spotted on X-Gal indicator plates. The blue color of the colony reflects the interaction between the two proteins. Controls include T18 and T25 fusions to TolB and Pal, two proteins that interact but unrelated to the T6SS. (B) The C-terminal domain of VgrG1 is required and necessary for Tle1^{EAEC} co-immunoprecipitation. The soluble lysate from 10¹¹ *E. coli* K-12 W3110 cells producing VSVG-tagged Tle1^{EAEC} (Tle1_{Vs}) alone (-, empty vector) or mixed with soluble lysates of W3110 cells producing the FLAG-tagged full-length (VgrG_F) or variants of VgrG1 represented in panel (C) were immunoprecipitated on anti-FLAG-coupled beads. The immunoprecipitated material was subjected to 12.5%-acrylamide SDS-PAGE and immunodetected with anti-FLAG (upper panel) and anti-VSVG (lower panel) monoclonal antibodies. Molecular weight markers (in kDa) are indicated on the left. The asterisks indicate the position of the antibody heavy chain. (C) Schematic representation of the EAEC VgrG1 protein and of the truncated variants used in this study. The different domains (and their boundaries) are indicated (gp27 and gp5 structural core; cc, coiled-coil; DUF, DUF2345; TTR, transthyretin-like region). (D) The TTR C-terminal region of VgrG1 is necessary and sufficient for the interaction with Tle1^{EAEC}. BTH101 reporter cells producing Tle1^{EAEC} fused to the T25 domain, and the indicated VgrG1 fragments fused to the T18 domain of the *Bordetella* adenylate cyclase were spotted on X-Gal indicator plates. The blue color of the colony reflects the interaction between the two proteins. Controls include T18 and T25 fusions to TolB and Pal, two proteins that interact but unrelated to the T6SS.


Figure 8. The VgrG1 CTD is required for antibacterial activity but not for T6SS assembly. (A)





The VgrG1 CTD is required for Tle1-dependent killing. The anti-bacterial activity was assessed by mixing W3110 *gfp*⁺ prey cells with the indicated attacker cells: WT (EAEC 17-2), Δ T6SS-1 (*sci-1* gene cluster deletion derivative) and Δ vgrG (17-2 deleted of *vgrG1* gene) carrying the pBAD18 and pMS600 empty vectors, or producing the indicated proteins (western-blot analyses shown in the inset), for 4 hours at 37°C in *sci-1*-inducing medium containing 0.02 % arabinose. The image of a representative bacterial colony is shown and the relative fluorescent levels (in arbitrary units, AU) are indicated in the upper graph. The number of recovered *E. coli* prey cells is indicated in the lower graph (in log₁₀ of colony-forming units (cfu)). The circles indicate values from three independent assays, and the average is indicated by the bar. (B) The VgrG1 CTD is not required for proper assembly and function of the Sci-1 T6SS. Hcp release was assessed by separating whole cells (C) and supernatant (SN) fractions from WT (EAEC 17-2), Δ T6SS-1 (*sci-1* gene cluster deletion derivative) and Δ vgrG1 (17-2 deleted of *vgrG1* gene) carrying the pMS600 empty vector or producing the indicated VgrG1 variant, and pBAD-Hcp_{VSVG}. 1×10⁸ total cells and the TCA-precipitated material from the supernatant of 2×10⁸ cells were subjected to SDS-PAGE and immunodetection using anti-VSVG monoclonal antibody (lower panel) and anti-TolB polyclonal antibodies as a lysis control (upper panel). The molecular weight markers (in kDa) are indicated on the left.

















A**B****C****D**

A**B**

A**B****C****D**



SUPPLEMENTARY INFORMATION

A phospholipase A₁ anti-bacterial T6SS effector interacts directly with the C-terminal domain of the VgrG spike protein for delivery

Nicolas Flaugnatti, Thi Thu Hang Le, Stéphane Canaan, Marie-Stéphanie Aschtgen, Van Son Nguyen, Stéphanie Blangy, Christine Kellenberger, Alain Roussel, Christian Cambillau, Eric Cascales, and Laure Journet

Supplemental Table S1. Strains, plasmids and oligonucleotides used in this study.

Figure S1. Tle1 and Tli1 are not necessary for T6SS assembly.

Figure S2. The Tli1 proteins in EAEC strains.

Figure S3. Tle1^{EAEC} does not co-immunoprecipitate with Hcp1.

Figure S4. Tle1^{EAEC} clusters with T6SS phospholipases of the Tle1 family.

Figure S5. Tle1 family members bear a characteristic GXSRG motif.

Supplemental Table S1. Strains, plasmids and oligonucleotides used in this study.

Strains

Strains	Description and genotype	Source
Enterotoxigenic <i>E. coli</i>		
17-2	Wild-type enterotoxigenic <i>Escherichia coli</i>	Arlette Darfeuille-Michaud
17-2 $\Delta tle1-tli1$	17-2 deleted of the <i>sci-1 tle1</i> and <i>tli1</i> genes	This study
17-2 $\Delta tli1-tli1b$	17-2 deleted of the <i>sci-1 tli1</i> and <i>tli1b</i> genes	This study
17-2 $\Delta T6SS-1$	17-2 deleted of the <i>sci-1</i> gene cluster	This study
17-2 $\Delta vgrG1$	17-2 deleted of the <i>sci-1 vgrG1</i> gene	(1)
<i>E. coli</i> K12		
DH5 α	F-, $\Delta(argF-lac)U169$, <i>phoA</i> , <i>supE44</i> , $\Delta(lacZ)M15$, <i>relA</i> , <i>endA</i> , <i>thi</i> , <i>hsdR</i>	Laboratory collection
W3110	F-, λ -IN(<i>rrnD-rrnE</i>)1 <i>rph-1</i>	Laboratory collection
BTH101	F-, <i>cya99</i> , <i>araD139</i> , <i>galE15</i> , <i>gacK16</i> , <i>rpsL</i> , <i>hsdR</i> , McrA1 McrB1	(2)
OP50	Wild-type strain used for <i>C. elegans</i> feeding	Steve Garvis
<i>Burkholderia cenocepacia</i>		
K56-2	Wild-type isolate	Carlos Gonzalez

Plasmids

Vectors	Description	Source
pCP20	FLP ⁺ , λ cI857 ⁺ , λ p _R Rep ^{ts} , Amp ^R , Cm ^R	(3)
pETG20A	Gateway® vector, 6-His-TRX followed by a TEV cleavage site, Amp ^R	Arie Geerlof
pETG20A-Tle1	<i>sci-1 tle1</i> cloned upstream the TEV cleavage site into pETG20A	This study
pETG20A-Tle1 ^{S197A}	<i>sci-1 tle1</i> _{S197A} cloned upstream the TEV cleavage site into pETG20A	This study
pETG20A-Tli1	<i>sci-1</i> signal sequence less <i>tli1</i> (residues 20 to 225) cloned upstream the TEV site into pETG20A	This study
pASK-IBA37(+)	Expression vector, AHT-inducible, Amp ^R	IBA technology
pASK-IBA4	Expression vector, AHT-inducible, OmpA signal sequence, Strep-tag, Amp ^R	IBA technology
pMS600	pOK12, C-terminal HA epitope, Kan ^R	(4)
pOK-HcpHA	<i>sci-1 hcp</i> cloned into pOK12, C-terminal HA epitope, Kan ^R	(5)
pBAD18	pBR322 <i>ori</i> , pAra, Amp ^R	(6)
pBAD33	pACYC-184 <i>ori</i> , pAra, Cm ^R	(6)
pEB354	pKT25 derivative, Kan ^R , p15A, Plac, T25 domain of <i>Bordetella</i> adenylate cyclase	(7)
pEB355	pUT18C derivative, Amp ^R , ColE1, Plac, T18 domain of <i>Bordetella</i> adenylate cyclase	(7)
pBAD18-Tle1	<i>sci-1 tle1</i> cloned into pBAD18, C-terminal VSVG epitope	This study
pBAD18-Tle1 ^{S197A}	<i>sci-1 tle1</i> _{S197A} cloned into pBAD18, C-terminal VSVG epitope	This study
pBAD18-Tle1-Tli1	<i>sci-1 tle1</i> and <i>tli1</i> cloned in tandem into pBAD18, C-terminal VSVG epitope	This study
pBAD18-Tle1 ^{S197A} -Tli1	<i>sci-1 tle1</i> _{S197A} and <i>tli1</i> cloned in tandem into pBAD18, C-terminal VSVG epitope	This study
pBAD18-Tli1 ^{EAEC}	<i>sci-1 tli1</i> cloned into pBAD18, C-terminal VSVG epitope	This study
pOK-Tli _{HA}	<i>sci-1 tli</i> cloned into pOK12, C-terminal HA epitope	This study
pASK-IBA37-FLAG	FLAG epitope inserted into pASK-IBA37(+)	This study
pASK-IBA37-Tli1 _{FLAG}	<i>sci1 tli1</i> cloned into pASK-IBA37(+), C-terminal FLAG epitope	This study
pBAD33-Tli1	<i>sci-1 tli1</i> cloned into pBAD33, C-terminal VSVG epitope	This study
pIBA-sp-MBP	signal sequence less <i>malE</i> cloned into pASK-IBA4, N-ter Strep-tag, OmpA signal sequence	This study
pIBA-sp-Tle1	<i>sci-1 tle1</i> cloned into pASK-IBA4, N-terminal Strep-tag epitope, OmpA signal sequence	This study
pIBA-sp-Tle1 ^{S197A}	<i>sci-1 tle1</i> _{S197A} cloned into pASK-IBA4, N-terminal Strep-tag epitope, OmpA signal sequence	This study
pOK-VgrG _{FLAG}	<i>sci-1 vgrG</i> cloned into pOK12, C-terminal FLAG epitope	This study
pOK-VgrG(1-778) _{FLAG}	<i>sci-1 vgrG</i> residues 1 to 778 cloned into pOK12, C-terminal FLAG epitope	This study

pOK-VgrG(1-615) _{FLAG}	<i>sci-1 vgrG</i> residues 1 to 615 cloned into pOK12, C-terminal FLAG epitope	This study
pOK-VgrG(1-573) _{FLAG}	<i>sci-1 vgrG</i> residues 1 to 573 cloned into pOK12, C-terminal FLAG epitope	This study
pT18-Pal	<i>pal</i> cloned downstream T18 into pEB355	(7)
pTolB-T25	<i>tolB</i> cloned upstream T25 into pEB354	(7)
pT25-Tle1	<i>sci-1 tle1</i> cloned downstream T25 into pEB354	This study
pT18-Tle1	<i>sci-1 tle1</i> cloned downstream T18 into pEB355	This study
pTle1-T25	<i>sci-1 tle1</i> cloned upstream T25 into pEB354	This study
pTli1 -T25	<i>sci-1</i> signal sequence less <i>tli1</i> (residues 20 to 225) cloned upstream T25 into pEB354	This study
pTli1 -T18	<i>sci-1</i> signal sequence less <i>tli1</i> (residues 20 to 225) cloned upstream T18 into pEB355	This study
pHcp1-T18	<i>sci-1 hcp</i> cloned upstream T18 into pEB355	(8)
pT18-Hcp1	<i>sci-1 hcp</i> cloned downstream T18 into pEB355	(8)
pT18-VgrG1	<i>sci-1 vgrG</i> cloned downstream T18 into pEB355	(8)
pVgrG1 –T18	<i>sci-1 vgrG</i> cloned upstream T18 into pEB355	(8)
pT18-PAAR	<i>sci-1 PAAR</i> cloned downstream T18 into pEB355	This study
pPAAR-T18	<i>sci-1 PAAR</i> cloned upstream T18 into pEB355	This study
pT18-VgrG1(1-778)	<i>sci-1 vgrG</i> residues 1 to 778 cloned downstream T18 into pEB355	This study
pT18-VgrG1(1-615)	<i>sci-1 vgrG</i> residues 1 to 615 cloned downstream T18 into pEB355	This study
pT18-VgrG1(1-573)	<i>sci-1 vgrG</i> residues 1 to 513 cloned downstream T18 into pEB355	This study
pT18-VgrG1(771-841)	<i>sci-1 vgrG</i> residues 771 to 841 cloned downstream T18 into pEB355	This study
pHcp _{FLAG}	<i>sci-1 hcp</i> cloned into pUC12, C-terminal FLAG epitope	(4)
pBAD-Hcp _{VSVG}	<i>sci-1 hcp</i> cloned into pBAD18, C-terminal VSVG epitope	This study

Oligonucleotides

For mutant construction ^a

17-2 *Δtle1-tli1*

DEL-4534-5/DW	<u>GTAAAAGTTGAGTTTGGGAAGGTAAAAATTCATGGAGAAACAGAATGACATGTGTAGGCTGGAGCTGCTTCG</u>
DEL-4534-3/DW	<u>GTGCGATAAAAATGATTTTATCTCTGGTCATGTATTGTCATCCTGTAGCGCATATGAATATCCTCCTTAGTTCC</u>

17-2 *Δtli1-tli1b*

DEL-4535-5/DW	<u>GTAAAAAATACTAAAGTTATGATGTCTGGTGTTTAACGCTACAGGATGACAATACTGTGTAGGCTGGAGCTGCTTCG</u>
DEL-4535-3/DW	<u>ATACAAAACCTTTAGACATAATACTCTCAAAAATAAATTTTCACTTTGAGCATATGAATATCCTCCTTAGTTCC</u>

17-2 *ΔT6SS-1*

DEL-4524-5/DW	<u>GGAGGCATCTGCGGTGATGGAACCCCTGAGATGCAGGTTT CACAGGAGAGAGCCTGTGTAGGCTGGAGCTGCTTCG</u>
DEL-4544-3/DW	<u>TCCAGCCCGCCAGTGAAATTGCCATAGAGAATTCATAAAGGGAAGGACGCGGCATATGAATATCCTCCTTAGTTC</u>

For plasmid construction ^{b, c, d}

pETG20A-Tle1

T6SS4534_p17Tev_F	GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTACTTCCAGGGT ACAAATATCAGGGATATGAC
T6SS4534_p17_R	GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTAAACACCAGACATCATAACTTTAG

pBAD18-Tle1

5pBAD-4534-VSVG	<u>CTCTCTACTGTTTCTCCATACCCGTTTTTTTTGGGCTAGCAGGAGGTATTACACCATGACAAAATATCAGGGATATG</u> ACGTA
3pBAD-4534-VSVG	<u>GGTCGACTCTAGAGGATCCCCGGGTACCTTATTTTCCTAATCTATTCAATTCAATATCTGTATAAACACCAGACAT</u> CATAACTTTAG

pBAD18-Tle1-Tli1

5pBAD-4534-VSVG	<u>CTCTCTACTGTTTCTCCATACCCGTTTTTTTTGGGCTAGCAGGAGGTATTACACCATGACAAAATATCAGGGATATG</u> ACGTA
3pBAD-4535-VSVG	<u>GGTCGACTCTAGAGGATCCCCGGGTACCTTATTTTCCTAATCTATTCAATTCAATATCTGTATACCAGTTACCGTAAGG</u> ATAAG

pBAD-Tli1^{EAEC} (pBAD18-Tli1) and pBAD33-Tli1

5pBAD-4535-VSVG CTCTCTACTGTTTCTCCATACCCGTTTTTTGGGCTAGCAGGAGGTATTACACCATGACCAGAGATAAAAATCATTTT
 TATC
3pBAD-4535-VSVG GGTCGACTCTAGAGGATCCCCGGGTACCTTATTTTCTAATCTATTCATTTCAATATCTGTATACCAGTTACCGTAAGG
 ATAAG

pOK-Tli_{HA}

5'EcoRI-4535 GTCG**GAATTC**ACCAGAGATAAAATCATTTTTATCGCACC
3'XhoI-4535 CTGC**CTCGAG**CCAGTTACCGTAAGGATAAGTTTTATCTCTG

pASK-IBA37-FLAG

pIBA37+FLAG-5 GAAGGAGATATACAAATGGCTAGCGGGGATTATAAGGACGACGATGACAAGTAAAGAGGATCGCATCACCATCACC
pIBA37+FLAG-3 GCTAGCCATTTGTATATCTCCTTCTTAAAGTTAAACAAAATTTC

pASK-IBA37-Tli1_{FLAG}

5-pIBA37-35 GTTTAACTTTAAGAAGGAGATATACAAATGACCAGAGATAAAATCATTTTTATCGC
3-pIBA37-35 CGTCGTCCTTATAATCCCCGCTAGCCCAGTTACCGTAAGGATAAGTTTTATCTC

pIBA-sp-MBP

5-pIBA4-MBP CCACCCGCAGTTCGAAAAGGCGCCAAAATCGAAGAAGGTAAACTGGTAATC
3-pIBA4-MBP GAGCTCGAATTCGGGACCGCGGTCTCTTACTTGGTGATACGAGTCTGC

pIBA-sp-Tle1

IBA4-4534-5	<u>CCACCCGCAGTTCGAAAAAGGCGCCACAAAATATCAGGGATATGACG</u>
IBA4-4534-3	<u>GAGCTCGAATTCGGGACCGCGGTCTCTTAAACACCAGACATCATAACT</u>

pOK-VgrG_{FLAG}

EcoRI-4533-5 GTCG**GAA**TTCAATCTCACTGACTCCCTGCAAAATGTTTTATC
XhoI-4533-3 GATC**CTC**GAGTTACTT**GTCA**TCGTCGTCCTTATAATCTTCTGTTTCTCCATGAATTTTTAC

pOK-VgrG(1-778)_{FLAG}

EcoRI-4533-5 GTCG**GAA**TTCAATCTCACTGACTCCCTGCAAATGTTTTATC
XhoI-4533delTTRFlag-3 GATC**CTCGAG**TACTTGTCATCGTCGTCCTTATAATCCCCAAACCCTCGCGGCATTTT

pOK-VgrG(1-615)_{FLAG}

EcoRI-4533-5

GTCGGAATTCAATCTCACTGACTCCCTGCAAAATGTTTTATC

XhoI-4533DelDUFFlag

GATCCTCGAGTTACTTGTATCGTCGTCCTTATAATCATTCAACCGTTGCTGACAAC

pOK-VgrG(1-573)_{FLAG}

EcoRI-4533-5

GTCGGAATTCAATCTCACTGACTCCCTGCAAAATGTTTTATC

XhoI-4533DelccDUFFlag

GCTACTCGAGTTACTTGTATCGTCGTCCTTATAATCCTTTCCTTGTGCCTGAGGCTGC

pT25-Tle1

T25N-4534-5

GGCGGGCTGCAGATTATAAAAGATGACGATGACAAGACAAAATATCAGGGATATGACG

T25T18N-4534-3

CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTAAACACCAGACATCATAACTTTAG**pT18-Tle1**

T18N-4534-5

CGCCACTGCAGGGATTATAAAAGATGACGATGACAAGACAAAATATCAGGGATATGACG

T25T18N-4534-3

CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTAAACACCAGACATCATAACTTTAG**pTle1-T25**

T25T18C-4534-5

CGGATAACAATTTACACACAGGAAACAGCTATGACCATGACAAAATATCAGGGATATGACG

T25C-4534-3

GTTTGCGTAACCAGCCTGATGCGATTGCTGAACACCAGACATCATAACTTTAG**pTli1-T25**

T25T18C-4535-5

CGGATAACAATTTACACACAGGAAACAGCTATGACCATGAATTCGGTTAGCTCACGGTATGC

T25C-4535-3

GTTTGCGTAACCAGCCTGATGCGATTGCTGCCAGTTACCGTAAGGATAAGTTTTATCTC**pTli1-T18**

T25T18C-4535-5

CGGATAACAATTTACACACAGGAAACAGCTATGACCATGAATTCGGTTAGCTCACGGTATGC

T18C-4535-3

CCTCGCTGGCGGCTAAGCTTGCGTAATCCAGTTACCGTAAGGATAAGTTTTATCTC**pT18-PAAR**

T18N-5-4537

CGCCACTGCAGGGATTATAAAAGATGACGATGACAAGTCTAAAGGTTTTGTATTGCTTGGTG

T25T18N-3-4537

CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTATCCTATTGCACATTCCGGTG**pPAAR-T18**

T25T18C-5-4537

CGGATAACAATTTACACACAGGAAACAGCTATGACCATGTCTAAAGGTTTTGTATTGCTTGGTG

T18C-3-4537

CCTCGCTGGCGGCTAAGCTTGCGTAATTCCTATTGCACATTCCGGTG

pT18-VgrG1(1-778)
T18N-4533-5 CGCCACTGCAGGGATTATAAAGATGACGATGACAAGAATCTCACTGACTCCCTGCAAAATGTTTTATCC
T25T18N-4533delTTR-3 CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTACCCAAACCTTCGCGGCATTTC

T25T18N-4533delTTR-3 CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTACCCAAACCCTCGCGGCATTTC

pT18-VgrG1(1-615)
T18N-4533-5 CGCCACTGCAGGGATTATAAAGATGACGATGACAAGAATCTCACTGACTCCCTGCAAAATGTTTTATCC
T25T18N-4533delDUF-3 CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTAATTC AACCGTTGCTGACA ACTTATATCTC

T25T18N-4533delDUF-3 CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTAATTCAACCGTTGCTGACAACTTATATCTC

pT18-VgrG1(1-573)
T18N-4533-5 CGCCACTGCAGGGATTATAAAGATGACGATGACAAGAATCTCACTGACTCCCTGCAAAATGTTTTATCC
T25T18N-4533delCCDUF-3 CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTACTTTCCTTGTGCCTGAGGCTG

T25T18N-4533delCCDUF-3 CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTACTTTCCTTGTGCCTGAGGCTG

pT18-VgrG1(771-841)
T18N-4533-5 CGCCACTGCAGGGATTATAAAGATGACGATGACAAGAATCTCACTGACTCCCTGCAAAATGTTTTATCC
T25T18N-4533delTTR-3 CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTACCCAAACCTCGCGGCATTTC

T25T18N-4533delTTR-3 CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCTAGTTACCCAAACCCTCGCGGCATTTC

pBAD18-Hcp _{VSVG}	
pBAD-Hcp1-5	<u>CTCTCTACTGTTTCTCCATACCCGTTTTTTTGGGCTAGCAGGAGGTATTACACCATGGCAATTCCAGTTTATCTGTGG</u> CTG
pBAD-Hcp1-VSVG-3	<u>GGTCGACTCTAGAGGATCCCCGGGTACCTTATTTTCCTAATCTATTCAATTCATATCTGTATACGCGGTGGTACGCTCAC</u> TCC

	CTG
--	-----

pBAD-Hcp1-VSVG-3 GGTCGACTCTAGAGGATCCCCGGGTACCTTATTTTCCTAATCTATTCAATATCTGTATACGCGGTGGTACGCTCAC
TCC

For site-directed mutagenesis ^e

A-4534S197A	GTTTGATGTTTTTGGTTTTgcCCGGGGAGCAGCGGCGGC
B-4534S197A	GCCGCCGCTGCTCCCCGgcaAAAACCAAAAACATCAAAC

B-4534S197A GCCGCCGCTGCTCCCCG^G_{gc}AAAACCAAAAACATCAAAC

^a sequences corresponding to the downstream and upstream regions of the gene to be deleted underlined.

^b sequence annealing to the target vector underlined.

^c FLAG or VSVG tag coding sequence italicized.

^d restriction site in bold.

^e mutagenized bases in lower case




Figure S1. Tle1 and Tli1 are not necessary for T6SS assembly. Hcp release assay. Hcp release was assessed by separating whole cells (C) and supernatant (SN) fractions from EAEC 17-2 (WT), or its $\Delta sci-1$ gene cluster ($\Delta T6SS-1$) or $\Delta tle1-tli1$ mutant derivative producing Hcp_{HA} (from the pOK-Hcp_{HA} plasmid). A total of 1×10^8 cells and the TCA-precipitated material from the supernatant of 2×10^8 cells were subjected to SDS-PAGE and immunodetection using anti-HA monoclonal antibody (lower panel) and anti-TolB polyclonal antibodies as a lysis control (upper panel). The molecular weight markers (in kDa) are indicated on the left.




Figure S3. Tle1^{EAEC} does not co-immunoprecipitate with Hcp1. Soluble lysates from 10¹¹ *E. coli* K-12 W3110 cells producing VSVG-tagged Tle1 (Tle1_{VS}) alone or mixed with soluble lysates of W3110 cells producing FLAG-tagged Hcp (Hcp_{FL}) were subjected to immunoprecipitation with anti-FLAG-coupled beads. The total soluble (Total) and the immunoprecipitated (IP) material were separated by 12.5%-acrylamide SDS-PAGE and immunodetected with anti-VSVG (upper panel) and anti-FLAG (lower panel) monoclonal antibodies. Molecular weight markers (in kDa) are indicated on the left.




Figure S4. Tle1^{EAEC} clusters with T6SS phospholipases of the Tle1 family. Phylogenetic analyses of Tle1^{EAEC} (EC042_4534; indicated by the arrow) with representative members of the Tle1-5 families identified by Russell *et al.*, 2013. Each Tle family is represented by a color code. Figure prepared using Phylogeny.fr (Dereeper *et al.*, 2008).

EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

GxSxG motif
 S197
 EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

D245
 EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

H310
 EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

EC042_4534
 ZP_17126626
 ZP_05133435
 YP_003748701
 YP_002396321
 YP_001478026
 YP_005954437
 NP_251980
 YP_004594328
 YP_443213
 YP_005627674
 ZP_05828070
 NP_899682

Figure S5. Tle1 family members bear a characteristic GXSRG motif. Sequence alignment of Tle1^{EAEC} (EC042_4534) with representative members of Tle1 family identified by Russell *et al.*, 2013. The alignment highlights the GXSXG motif (GFSRG) of the Tle1 family that is conserved in Tle1^{EAEC}. The predicted S197, D245, and H310 residues of the catalytic triad are indicated by stars. Figure prepared using MultAlin (9).

Supplemental references

1. Brunet, Y.R, Hénin, J., Celia, H., and Cascales, E. (2014) Type VI secretion and bacteriophage tail tubes share a common assembly pathway. *EMBO Rep.* **15**: 315-21.
2. Karimova, G., Pidoux, J., Ullmann, A., and Ladant, D. (1998) A bacterial two-hybrid system based on a reconstituted signal transduction pathway. *Proc. Natl. Acad. Sci. U.S.A.* **95**: 5752-5756
3. Cherepanov, P. P. and Wackernagel, W. (1995) *Gene* **158**: 9–14.
4. Aschtgen, M. S., Bernard, C. S., De Bentzmann, S., Lloubes, R., and Cascales, E. (2008) SciN is an outer membrane lipoprotein required for type VI secretion in enteroaggregative *Escherichia coli*. *J. Bacteriol.* **190**: 7523-7531
5. Aschtgen, M. S., Gavioli, M., Dessen, A., Lloubes, R., and Cascales, E. (2010) The SciZ protein anchors the enteroaggregative *Escherichia coli* Type VI secretion system to the cell wall. *Mol. Microbiol.* **75**: 886-899
6. Guzman, L.M, Belin, D, Carson M.J, Beckwith, J. (1995) Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. *J. Bacteriol.* **177**: 4121-30
7. Battesti, A., and Bouveret, E. (2006) Acyl carrier protein/SpoT interaction, the switch linking SpoT-dependent stress response to fatty acid metabolism. *Mol. Microbiol.* **62**: 1048-1063
8. Zoued, A., Durand E., Bebeacua C., Brunet Y.R., Douzi B., Cambillau C., Cascales E., Journet L. (2013) TssK is a trimeric cytoplasmic protein interacting with components of both phage-like and membrane anchoring complexes of the Type VI secretion system. *J. Biol Chem.*, **288**: 27031-41
9. Corpet, F. (1988) Multiple sequence alignment with hierarchical clustering. *Nucl. Acids Res.*, **16**:10881-10890
10. Robert, X., and Gouet, P. (2014) Deciphering key features in protein structures with the new ENDscript server. *Nucl. Acids Res.* **42**:W320-W324